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Multiple myeloma (MM) is characterized by the accumulation of monoclonal plasma cells in 
the bone marrow. Previously, treatment was initiated after diagnosis of symptomatic MM, 
which requires evidence of specific end-organ damage. This is defined by the CRAB features; 
hypercalcemia (C), renal impairment (R), anemia (A) or bone lesions (B). Nowadays high 
tumour load is another reason to start treatment. Systemic treatment can also be initiated 
with more than 60% plasma cells in the bone marrow, a serum-free light chain ratio ≥ 100, 
and more than 1 focal lesion detected on MRI.
Osseous involvement is a predominant feature of MM. Lytic bone lesions develop in 90% of 
MM patient’s, which is an important cause of morbidity, resulting in pain and in some cases 
in pathologic fractures. These lesions are caused by increased bone resorption and reduced 
bone formation. Detecting bone lesions is an important part of the diagnostic process of 
symptomatic MM. Detection of osseous involvement means that treatment is indicated. This 
highlights the need for an accurate diagnosis of bone involvement. Until recently, whole body 
X-ray (WBX) was the only diagnostic tool. However, this technique has several limitations; 
it can only detect lesions that have lost more than 30% of the trabecular bone, and no 
extramedullary disease can be shown. Its value in relapsing disease is also limited since bone 
lesions persist post-treatment. No distinction can be made between old and new lesions, so 
it has little value for disease monitoring. 
In recent years, alternative techniques have been developed to diagnose osseous 
involvement. Low dose whole body CT (WB-CT), MRI and PET/CT scans have been introduced 
for the detection of active bone lesions. An alternative approach to imaging MM activity is to 
target cellular properties of MM cells or their micro-environment. This can be accomplished 
by using different radiolabeled compounds to visualize the affected skeleton areas. The use 
of nuclear medicine imaging provides a high sensitivity technique for detecting bone lesions. 
In addition, it can be used to monitor treatment response, thereby providing prognostic 
information.
The treatment of MM has improved substantially during the last decade. Several novel 
agents have become available for treating MM patients, such as bortezomib, lenalidomide 
and thalidomide. In the recent years carfilzomib, pomalidomide and daratumumab 
have been added to the therapeutic options. First-line treatment for younger patients 
consists of chemotherapy, including novel agents, followed by an autologous stem cell 
transplantation (ASCT). Patients ineligible for ASCT are treated with an combination regime, 
including melphalan, prednisolone and a novel agent or the combination lenalidomide and 
dexamethasone. Due to the introduction of these new regimens, the overall survival (OS) 
has improved considerably. Despite these improvements, however, MM relapses frequently 










































whether prolonged maintenance treatment with one of the novel agents with or without 
cyclophosphamide might extend progression-free survival (PFS).
MM is often complicated by venous thromboembolism (VTE) despite the widespread use 
of thrombosis prophylaxis. In the studies published so far, the described incidence of VTE 
varies between 5-10%. A higher incidence might be demonstrated in a non-selected patient-
population, which might change the strategy of thrombosis prophylaxis in newly diagnosed 
MM patients.
In some cases, MM does not present diffusely through the body, but as a solitary lesion, 
known as a solitary plasmacytoma. These plasmacytomas can be present not only in the 
bone but also extramedullary, which has important prognostic value for the development 
of systemic disease. More accurate identification of patients who develop MM following 
plasmacytoma treatment might provide tools for an early intervention strategy.
Beside plasmacytoma there are several other rare diseases linked to M-protein production 
such as scleromyxedema. In this disease a M-protein is present, but the presenting symptoms 
frequently indicate widespread organ involvement. Treatment of this complicated disease 
consists of drugs that are also used for MM patients. Diagnosing this disease is challenging. 
The aim of this thesis is to evaluate multiple aspects of the malignant plasma cell by studying 
several imaging techniques, analyzing treatment regimens, and studying the progression of 
plasmacytoma to MM. In addition the incidence of VTE as a complication of disease activity 
and treatment is evaluated. Finally a rare disease, scleromyxedema, which is related to the 
malignant plasma cell, is discussed.
Scope of the thesis
Chapter 2 addresses the background and use of several nuclear imaging techniques in 
relapsing MM. Chapter 3 focuses on the use of somatostatin receptor scintigraphy (SRS) in 
relapsing MM, also compared to whole body X-ray. Chapter 4 describes the role of FDG-PET in 
patients with relapsing MM. This chapter also reports on in vitro and in vivo studies to monitor 
the involvement of hypoxia. Chapter 5 describes the efficacy of bortezomib, low dose oral 
cyclophosphamide and dexamethasone in patients with relapsed MM, including the beneficial 
effect of one year of maintenance with bortezomib and low dose oral cyclophosphamide. 
Chapter 6 addresses the prevalence of VTE, one of the major complications of treatment 
for MM, is studied. A retrospective analysis is performed evaluating the incidence of VTE 
in conjunction with the corresponding treatment and prophylaxis regimens. Chapter 7 
concerns a retrospective analysis of patients treated for solitary plasmacytoma in the 
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of angiogenesis. Chapters 8 highlights scleromyxedema a disease related to the plasma cell 
dyscrasia. Diagnostic and treatment options for patients with scleromyxedema are discussed. 









































































Nuclear medicine imaging of multiple myeloma, 
particular in the relapsed setting
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Multiple myeloma (MM) is characterized by a monoclonal plasma cell population in the 
bone marrow. Lytic lesions occur in up to 90% of patients. For many years, whole body 
X-ray (WBX) was the method of choice for detecting skeleton abnormalities. However, the 
value of WBX in relapsing disease is limited because lesions persist post-treatment, which 
restricts the capacity to distinguish between old, inactive skeletal lesions and new, active 
ones. Therefore alternative techniques are necessary to visualize disease activity. Modern 
imaging techniques such as magnetic resonance imaging, positron emission tomography and 
computed tomography offer superior detection of myeloma bone disease and extramedullary 
manifestations. In particular, the properties of nuclear imaging enable the identification of 
disease activity by directly targeting the specific cellular properties of malignant plasma cells. 
In this review an overview is provided of the effectiveness of radiopharmaceuticals that target 
metabolism, surface receptors and angiogenesis. The available literature data for commonly 
used nuclear imaging tracers, the promising first results of new tracers, and our pilot work 
indicate that a number of these radiopharmaceutical applications can be used effectively 
for staging and response monitoring of relapsing MM patients. Moreover, some tracers can 
potentially be used for radio immunotherapy.
Key Words: Relapsing multiple myeloma, radiopharmaceutical applications, nuclear medicine, 













































Multiple Myeloma, diagnosis and treatment
Multiple myeloma (MM) is a disease characterized by a monoclonal plasma cell population in 
bone marrow. In most cases, the diagnosis of MM is based on the presence of a monoclonal 
M-protein or free-light chain in the blood and at least 10% plasma cells in the bone marrow. 
Treatment is initiated when MM is symptomatic according to CRAB features: hypercalcemia 
(C), renal impairment (R), anemia (A) or bone lesions (B). Currently, patients with more than 
60% monoclonal plasma cells in their bone marrow, a free light chain ratio greater than 100, 
or more than 1 focal bone or bone marrow lesion on the MRI are classified as high risk for 
development of MM, and should also receive treatment1. 
First-line treatment for patients younger than 70 years and eligible for autologous stem cell 
transplantation (ASCT) consists of induction chemotherapy, including a proteasoom inhibitor 
or an immunomodulator agent like bortezomib, lenalidomide or thalidomide, followed by 
ASCT2,3. Patients ineligible for ASCT are treated with a combination of melphalan, prednisolone 
and a novel agent, or with the combination of lenalidomide and dexamethasone4,5. Following 
the introduction of these regimens, the overall survival (OS) improved considerably: the 
5-year OS for younger MM patients is now 70%, and for older patients 41%6.  
Multiple Myeloma and imaging
Whole body X-ray, MRI and low dose CT scan
Asymptomatic MM is distinguished from symptomatic MM through the CRAB criteria. Bone 
lesions play an important role since lytic bone lesions develop in 90% of the patients during 
the disease. These lesions, are an important cause of morbidity, resulting in pain and in some 
cases in pathologic fractures7. Lytic bone lesions are the result of increased bone resorption 
and reduced bone formation8. Detecting bone lesions is an important part for the diagnosis 
of symptomatic MM since having bone lesions means treatment is indicated. This highlights 
the need for accurate investigation of bone disease. Until recently, whole body X-ray (WBX) 
was the method of choice. This technique has several limitations: it can only detect lesions 
that have lost more than 30% of the trabecular bone7, and no extramedullary disease can 
be shown. The value in relapsing disease is limited since lesions persist post-treatment. No 
distinction can be made between old vs. new lesions and therefore it is of limited value for 
disease monitoring. 
In recent years, alternative techniques have been developed to visualize MM activity. Low 
dose whole body CT (WB-CT), MRI and PET/CT are introduced for the detection of (active) 










































for the diagnosis of symptomatic MM evidence of one or more (>5mm in size) osteolytic bone 
destruction lesions seen on CT or PET-CT does fulfill the criteria for bone disease, thereby 
fulfilling the CRAB criteria1. The guideline also recommends performing a PET-CT, CT or MRI 
of the whole body or spine in all patients suspected of asymptomatic MM to exclude bone 
involvement1. Nowadays MRI and WB-CT scanning have been implemented in many parts 
of the world for detecting myeloma lesions. WB-CT scan has a higher detection rate of lytic 
lesions compared with WBX but in some studies lesions in the skull and ribs were less well 
detected with WB-CT, while other studies suggested a better detection rate with WB-CT9,10. 
Other advantage of WB-CT is the fact that radiation exposure is comparable with WBX, and 
no intravenous contrast is needed10. 
MRI is used for detection of spinal cord compression and to differentiate myeloma from non-
myeloma vertebral fractures. MRI has a high detecting rate of bone marrow involvement. MRI 
provides the opportunity to visualize bone marrow infiltration rather than defining osteolytic 
lesions. Therefore in newly diagnosed patients MRI may be less helpful since it detects 
bone lesions earlier than the myeloma-related bone destruction has occurred. In case of 
monoclonal gammapathy of unknown significance (MGUS), asymptomatic MM or solitary 
plasmacytoma of the bone, MRI can be used to distinguish high risk patient for developing 
symptomatic MM. Patients with more than one focal lesion on the MRI are classified as high 
risk for development of MM10,11. 
An alternative manner of imaging MM activity is to target cellular properties of MM cells or 
micro-environment which can be accomplished by using different radiolabeled compounds 
to visualize the affected skeleton areas. 
Target mechanism in nuclear imaging
Positron emission tomography (PET) imaging is now widely used for the detection and follow-
up of malignant disorders. In MM, PET tracers are used especially for detecting medullary and 
extramedullary disease. These nuclear tracers can also provide information about the degree 
of uptake by the lesions of interest, which is indicated by calculation of the standardized 
uptake value (SUV). In addition, PET scanning has shown promise for monitoring treatment 
response, since increase or decrease can be visualized and/or calculated compared to a 
baseline scan12. Recently, various specific PET tracers have been developed which might be 
useful in the workup of patients with newly diagnosed and relapsing MM. In the present 
review, we evaluate several nuclear tracers and nuclear imaging techniques as defined by 
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Table 1: Various nuclear imaging techniques (PET and SPECT) and their targets.
Mechanism of action Tracer Target
Cell metabolism
Glucose [18F]-FDG Glucose uptake
 Amino acid [11C]-MET Methionine 
[18F]-FAMT L-type aminoacid transporter 1
Nucleotide [18F]-FLT Activity of thymidine kinase
[11C] -4DST  Activity of thymidine kinase
Membrane metabolism [11C]-ACT Acetate/fatty acid synthesis 
[11C]-choline Choline
Receptor targeting
Somatostatin receptor scintigraphy [111In]-pentetreotide Somatostatin receptor 






hypoxia [18F]-FAZA Hypoxia 
Angiogenesis [89Zr]-bevacizumab Circulating VEGF
Legend: [18F]-FDG: [18F]-fluorodeoxyglucose, [11C]-MET: [11C]-Methionine, [18F]-FAMT: [18F]-
alpha-methyltyrosine, [18F]-FLT: [18F]-fluoro-3-deoxy-L-thymidine, [11C]-4DST: Methyl-11C-40- 
thiothymidine, [11C]-ACT: [11C]-acetate, [18F]-FAZA: 1-α-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-















































































Legend: Malignant plasma cell with surrounding stromal cells and it potential targets for nuclear 
imaging. LAT-1: L-type amino-acid transporter 1, SST: Somatostatin receptor, VEGF: vascular endothelial 
growth factor, GLUT: glucose transport proteins, TC+: [99mTc]-sestamibi/[99mTc]-tetrofosmin, CXCR4: 
Chemokine receptor 4, VLA: Very-late-antigen-4, VCAM: vascular cell adhesion molecule, FLT: fluoro-3-
deoxy-L-thymidine, TK: thymidine kinase, CD: cluster of differentiation.
Cell metabolism
A: Glucose
[18F]-fluorodeoxyglucose ([18F]-FDG-PET) uses enhanced glucose metabolic activity to 
visualize areas of interest13. [18F]-FDG, a glucose analogue, is actively transported into cells 
mediated by a group of structurally related glucose transporter proteins (GLUT). Tumor cells, 
including MM cells, show increased numbers of these glucose transporters, particularly GLUT-
1 and GLUT-314. Glucose and [18F]-FDG are phosphorylated intracellularly by hexokinase. In 
contrast to glucose, [18F]-FDG undergoes no further metabolism in the glucose pathway 
and becomes trapped intracellularly as [18F]-FDG-6-phosphate15. The use of [18F]-FDG-PET 
as baseline scan has been studied extensively in newly diagnosed MM patients. Based on 
the number of focal lesions and the maximum SUV (SUV
max
), [18F]-FDG-PET detects more 
lesions compared to WBX9. In addition follow-up [18F]-FDG-PET scans can be used to monitor 
treatment response and is of prognostic value for survival12. Complete normalization of the 
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survival (PFS) and overall survival (OS)12. This imaging technique may also be useful in patients 
with relapsing MM since it is not hampered by the presence of pre-existing skeletal defects 
since it visualizes areas of enhanced metabolic activity9,16-19. In relapsing MM patients, only 
a few studies have been performed with [18F]-FDG-PET14,20-22. Disease activity is shown on 
the [18F]-FDG-PET (Table 2A) in the majority of MM patients. A significantly higher number 
of positive lesions has been detected relative to WBX14. In about 25% of the patients with 
relapsing disease, no defects on [18F]-FDG-PET scan are shown, despite the presence of 
active disease. Comparable results have been reported in newly diagnosed MM patients, with 
24% of the patients having a negative [18F]-FDG-PET scan (Table 2A)12. This is probably due 
to a diffuse distribution of malignant plasma cells in the skeleton. Skull lesions smaller than 1 
cm are especially difficult to detect with [18F]-FDG-PET19, because of the high physiological 
uptake in the brain tissue. 
Table 2: [18F]-FDG-PET in relapsing multiple myeloma compared to various nuclear imaging 
techniques (PET and SPECT).
A
Study Tracer n MM % pos [18F]-FDG-PET 
De Waal 2015 [18F]-FDG 44 R 82%
Lapa 2014 [18F]-FDG 37 R 76%
Zamagni 2011 [18F]-FDG 192 ND 76%
McDonald 2016 [18F]-FDG 192 ND 68%
B
Study Tracer n MM pos scan vs pos [18F]-FDG-PET (%)
Okasaki 2015 [11C]-MET 10 R 100% vs 60%
Lapa 2016 [11C]-MET 43 32 R 91% vs 77%
Isoda 2012 [18F]-FAMT 11 8 R 73% vs 73%
Agool A 2006 [18F]-FLT 2 R very low uptake
Okasaki 2015 [11C] -4DST  10 R 80% vs 60%
Lin C 2014 [11C]-ACT 15 ND 86% vs 67%
Nanni C 2007 [11C]-choline 4 R 100% vs 100%
Cassou-Mounat 2016 [11C]-choline 21 R 71% vs 71%
De Waal 2012 [111In]-pentetreotide 18 R 52% vs 71%
Philipp-Abbrederis K 2015 [68Ga]-Pentixafor 14 R 71% vs 64% 
Fonti R 2015 [99mTc]-sestamibi 27 ND 89% vs 97%
De Waal 2015 [18F]-FAZA 5 R negative scan
De Waal, unpublised [89Zr]-bevacizumab 5 R negative scan
Legend: [18F]-FDG-PET in relapsing multiple myeloma. B: Studies with different nuclear imaging 
techniques (PET and SPECT) in multiple myeloma patients compared to [18F]-FDG-PET before treatment 
was started. [18F]-FDG: [18F]-fluorodeoxyglucose, [11C]-MET: [11C]-Methionine, [18F]-FAMT: [18F]-
alpha-methyltyrosine, [18F]-FLT: [18F]-fluoro-3-deoxy-L-thymidine, [11C] -4DST: Methyl-11C-40- 
thiothymidine, [11C]-ACT: [11C]-acetate, [18F]-FAZA: 1-α-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-










































Improvements have been made regarding uptake measurements with [18F]-FDG-PET. Total 
lesion glycolysis (TLG) and metabolic tumor volume (MTV) can be calculated from [18F]-FDG-
PET and might be an more accurately measurement than the conventional measurements 
predicting overall tumor burden of focal lesions in MM. In a recent study of newly diagnosed 
MM patients [18F]-FDG-PET was performed at baseline (table 2A). In this study a TLG 
>620g and MTV >210cm3 was found to be a significant predictor for a poorer PFS and OS23. 
Combining TLG and MTV with other risk factors like gene expression profiling (GEP) and ISS 
stage resulted in the identification of a high risk subgroup23.
The Italian group presented guidelines for uniforming [18F]-FDG-PET quantification by 
using a five point scale including: the metabolic state of the BM, number and site of focal 
[18F]-FDG-PET positive lesions with or without osteolytic characteristics, presence and 
site of extramedullary disease, presence of paramedullary disease (a bone lesion involving 
surrounding soft tissues with bone cortical interruption), and presence of fractures. The visual 
degree of uptake is defined for the target lesion and extramedullary lesions according to the 
Deauville criteria24. In a small series this five point scale seemed reproducible and can be 
used for comparing [18F]-FDG-PET scan from baseline to scans after treatment; furthermore 
it provides a guideline to uniform research data24. 
B: Amino acids 
Methionine, an amino acid required for protein synthesis, can be used for PET scanning. 
[11C]-Methionine ([11C]-MET) is frequently used for imaging brain tumours, since the 
physiological background uptake of [11C]-MET is low in the brain. Due to the active protein 
synthesis by the malignant plasma cells, this might also be a useful tracer for MM. In several 
studies, [11C]-MET was compared with [18F]-FDG-PET (Table 2B)25,26. Compared to [18F]-
FDG-PET, more lesions were detected with [11C]-MET, especially when a low number of 
aberrant plasma cells were present in the bone marrow (<30%)25. A limitation for widespread 
use of [11C]-MET is the short half-life of approximately 20 minutes, necessitating production 
by an on-site cyclotron. 
The amino acid transporter L-type amino-acid transporter 1 (LAT-1) is overexpressed in a 
number of tumors including MM. LAT-1 provides a transporter function for protein synthesis. 
The amino-acid tracer [18F]-alpha-methyltyrosine ([18F]-FAMT) is also transported by LAT-
1. The uptake of this tracer correlates with LAT-1 expression27. In relapsing MM patients, a 
comparison has been made between [18F]-FAMT and [18F]-FDG-PET. A comparable number 
of lesions were detected with both imaging techniques, but the SUVmax was significantly 
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C: DNA proliferation marker
Thymidine, a DNA nucleoside required for DNA-synthesis, can also be used as tracer. 
Fluorothymidine is an analogue of the nucleoside thymidine (deoxythymidine), and can be 
labeled to produce [18F]-fluoro-3-deoxy-L-thymidine ([18F]-FLT). FLT is transported into the 
cell and is a substrate for thymidine kinase-1 (TK1), which is related to DNA synthesis and is 
therefore a surrogate marker for cell proliferation28. Using [18F]-FLT PET scanning for solid 
malignancy, a high bone marrow background activity has been demonstrated, which indicates 
the proliferative activity of the hematopoietic cells in the bone marrow cavity29. Patients with 
MM were included in a pilot study using [18F]-FLT with haematological malignancies. Areas 
with skeletal lesions showed a very low uptake of [18F]-FLT compared to non-affected areas, 
which is in line with the low proliferative activity of MM cells30. Follow up scans with this 
tracer may be difficult since it has been shown that bone marrow cells undergo a phenotypic 
shift after chemotherapy and autologous stem cell transplantation, thereby altering their 
cycling time and the uptake seen on the [18F]-FLT-PET scan31. The new tracer Methyl-
[11C]-40-thiothymidine ([11C]-4DST) has shown more positive findings. [11C]-4DST is more 
stable than [18F]-FLT. Once [11C]-4DST is incorporated into DNA, dephosphorylation occurs 
relatively rare, unlike [18F]-FLT. This has also been shown in a study of MM patients, in which 
[11C]-4DST showed more positive findings per patient than [18F]-FDG-PET, particularly in 
patients with low numbers of bone marrow plasma cells (Table 2B)25. 
D: Membrane
Acetate is an important metabolite that is used to synthesize amino acids, nucleotides and 
fatty acids. When ligated to coenzyme A (acetyl-CoA), it can be converted into fatty acids32. 
[11C]-acetate ([11C]-ACT) can be, like the natural precursor acetate, converted into fatty 
acids. In cell lines it has been demonstrated that MM cells have a higher metabolic activity 
involving free fatty acids28. In newly diagnosed MM patients, [11C]-ACT PET identified more 
focal lesions than [18F]-FDG PET (table 2B)33. This result is promising, but needs to be verified 
in a larger number of patients, including relapsing MM patients. An additional player in fatty 
acid metabolism is choline, which is phosphorylated by choline kinase and incorporated into 
various phospholipids. In prostate cancer, [11C] or [18F]-Choline has frequently been used for 
monitoring disease activity. In two studies with [11C]-Choline PET scanning in MM patients, 
the number of positive scans were similar when [11C]-Choline was compared with [18F]-FDG-
PET, but more focal lesions were detected with [11C]-Choline than with [18F]-FDG-PET)34,35. 
Cluster of differentiation (CD)38, which is a glycoprotein functioning in cell adhesion, signal 
transduction and calcium signaling36. CD38 is highly expressed on myeloma cells, but at 
relatively low levels on normal hematopoietic cells and in some tissues of non-hematopoietic 










































has been developed. This drug is promising in the treatment of MM. Treatment with 
daratumumab monotherapy in relapsed and refractory MM patients did have a significant 
effect on PFS36. Phase 3 trials combining daratumumab with conventional treatments such 
as bortezomib and lenalidomide are ongoing. Use of radiolabeled anti-CD38 could be a 
promising approach not only for diagnostic purposes and treatment monitoring, but it might 
also be used in the context of radioimmunotherapy due to the restricted expression of CD38 
on normal tissues. Preclinical studies have already been performed in xenograft mice models 
with radioimmunoconjugates consisting of the α-emitter [213Bi] coupled to the anti-CD38 
monoclonal antibody, with a significant targeting of CD3837.
CD138, or syndecan-1, is a member of the syndecan family, expressed by epithelial cells, 
precursor B cells, and normal plasma cells. CD138 is highly expressed on myeloma cells. 
Phase I-II studies have been initiated with anti-CD138, called Indatuximab38,39. Alpha-radio-
immunotherapy treatment using a [213Bi] -labeled anti-mouse CD138 antibody has been 
performed in mouse models, showing promising results. Mice treated with [213Bi]-CD138 
had a longer median survival than the control group40.
Receptor targeting
In vitro studies with plasma cell lines have shown that somatostatin receptors, especially 
subtypes 1, 2 and 5, are highly expressed on MM cells41. Somatostatin receptor scintigraphy 
(SRS) using the Single Photon Emission Computed Tomography (SPECT) tracer [111In]-
pentetreotide is able to visualize somatostatin receptors, especially subtypes 2 and 542. SPECT 
has by definition a lower spatial resolution and less quantification possibilities, compared 
to PET. Studies with SRS in MM patients have been performed specifically in relapsing MM 
patients. A positive SRS scan was reported in 83% of the patients, which is significantly higher 
than the results obtained with WBX43,44. However, when SRS was compared to [18F]-FDG-PET, 
the latter identified significantly more focal lesions44, which may be explained by the better 
resolution of PET compared to SPECT. SRS is also used in the workup of neuroendocrine 
tumors (NET). In this context [68Ga]-DOTA-TOC/TATE/NOC/lanreotide PET/CT is used, which 
has superior resolution and hence better sensitivity than the conventional SRS, thereby 
replacing SRS for staging NET45. Considering these properties, [68Ga]-DOTA subtypes might 
also be useful for diagnostic purposes in MM. 
Chemokine receptor 4 (CXCR4) is expressed on hematopoietic stem and progenitor cells 
residing in the bone marrow niche, which has an important function in the homing of these 
cells to the bone marrow compartment. Disrupting this interaction by Plerixafor, a CXCR4 
antagonist, results in mobilization of stem cells out of the bone marrow niche, a property used 
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system, including plasma cells. Approximately 50% of the MM cells express CXCR4 in high 
density46. [68Ga]-Pentixafor is a labeled peptide with high affinity for CXCR4, which has 
been studied in relapsing MM patients in comparison to [18F]-FDG-PET. The results showed 
that a high number of the MM patients have a positive [68Ga]-Pentixafor scan46 (Table 2B). 
Due to these promising results, the anti-CXCR4 antibody has been labeled with [177Lu]-
pentixather or [90Y]-pentixather with the aim of performing radio-immunotherapy. Recently, 
three heavily pretreated myeloma patients were treated with [177Lu]-pentixather or [90Y] 
-pentixather after CXCR4 expression was confirmed with a [68Ga]-Pentixafor PET scan. Two 
patients responded to treatment, showing a decrease in free light chain ratio and a reduction 
of SUVmax on the [18F]-FDG-PET scan. The third patient died due to sepsis 3 weeks after 
[177Lu]-pentixather therapy. PFS was short, and ranged between 3 and 6 months47. Based 
on these pilot studies, [68Ga]-Pentixafor scanning might be used to select patients treatment 
with radiolabeled [68Ga]-Pentixafor and to monitor the effects of therapy47. 
Another membrane receptor is the Very-late-antigen-4 (VLA-4, α4β1integrin, CD49d/CD29), 
which is a trans membrane adhesion receptor. VLA-4 is over-expressed on MM cells and 
plays a key role in the adhesion and spreading through the bone marrow compartment. 
VLA-4 binds to vascular cell adhesion molecule-1 (VCAM-1) and fibronectin of bone marrow 
stromal cells. The PET tracer [64Cu]-CB-TE1A1P-LLP2 is now under investigation in preclinical 
models48. 
Mitochondrial activity
[99mTc]-sestamibi and [99mTC]-tetrofosmin have been developed for myocardial perfusion 
SPECT imaging. These compounds consist of a lipophilic monovalent cation, which is 
sequestered in the mitochondria by the large negative membrane potential28. [99mTc]-
sestamibi SPECT has also been studied in MM and compared with [18F]-FDG-PET and MRI. 
In newly diagnosed MM patients, [18F]-FDG-PET detected more focal lesions than [99mTc]-
sestamibi (Table 2B)49, probably due to better spatial resolution and different target imaging. 
Furthermore [18F]-FDG-PET and [99mTc]-sestamibi detected more lesions, including 
extramedullary disease, than MRI49.
Angiogenesis & hypoxia
The increased FDG uptake by malignant MM cells is related to higher metabolic activity. This 
might be a consequence of tumour hypoxia resulting from increased O2 consumption by the 
malignant MM cells or due to altered micro-vascularisation of the bone marrow containing 
plasma cells. Due to hypoxia, hypoxia inducible factor (HIF)-1α and HIF-2α are produced by 
the malignant cells or by the surrounding endothelial cells, which triggers the production of 










































around the malignant plasma cells. Several studies have shown that increased MVD correlates 
with tumor progression50-52. A relatively low MVD has been observed in smouldering MM, 
which increases significantly during disease progression51. The PET tracer 1-α-D:-(5-deoxy-
5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ([18F]-FAZA), has been developed for 
visualizing in vivo tumor hypoxia. Under hypoxic conditions, two nitroimidazole compounds 
undergo reduction, forming highly reactive oxygen radicals and binding to macromolecules 
inside the cell. [18F]-FAZA has been used in patients with solid tumors, such as head and 
neck cancers and non-small cell lung cancers54,55. At our institute, five patients diagnosed 
with relapsing MM based on a positive [18F]-FDG-PET scan underwent [18F]-FAZA scanning. 
However, enhanced uptake of [18F]-FAZA was not demonstrated in any of the patients, 
despite the presence of focal disease (Figure 2a and b)14. These findings suggest that the 
degree of hypoxia is not substantially different in MM spots compared to the surrounding 
bone marrow compartment. An alternative approach might be to use tracers that bind to the 
VEGF produced by MM cells. This can be achieved by labeling bevacizumab, a recombinant, 
humanised monoclonal antibody that binds with high affinity to all isoforms of free human 
VEGF. Treatment with bevacizumab is well established in solid tumors such as colon cancers 
and renal cell carcinomas. [89Zr]-bevacizumab PET scanning has been used to detect solid 
tumors like breast cancer and demonstrated positive scans in 96% of the patients56. [89Zr]-
bevacizumab PET scanning was also performed in 5 relapsed MM patients (Fig 2c and d). All 
the patients had clinical progression of MM, and positive lesions were detected on [18F]-
FDG-PET. Unfortunately, no lesions were detected with [89Zr]-bevacizumab PET scanning in 
any of the patients.  
Figure 2: Various PET imaging in MM patients.
a    b     c     d 
Legend: A. [18F]-FDG-PET with diffuse hotspots in the skeleton and extramedullary. B. [18F]-FAZA of the 
same patient as A with no hot spots. C. [18F]-FDG-PET, hot spot in the sternum D. [89Zr]-bevacizumab 












































Various nuclear imaging techniques and tracers have been used for detecting disease activity 
and bone lesions in newly diagnosed MM patients, but few studies have been conducted in 
relapsed MM patients. Nuclear imaging can be helpful especially in relapsed MM because 
it is frequently difficult to detect new disease activity with WBX or MRI or bone marrow 
biopsy due to its scattered growth pattern. Additionally, nuclear imaging can be helpful in 
determining the response to treatment, which might have also prognostic significance for 
clinical outcome. As shown in Table 1 and Figure 1, the tracers used for nuclear imaging 
target different aspects of the cellular properties of the plasma cells. Most studies have been 
performed with [18F]-FDG-PET. [18F]-FDG-PET is widely used and available for patient care. In 
newly diagnosed MM, [18F]-FDG-PET detects more lesions, including extramedullary disease, 
compared to WBX and provides useful information about treatment response and outcome. 
Currently WB-CT-scan is replacing WBX as standard of care for detection of skeleton lesions. 
The use of nuclear tracers provides additional information especially about the metabolic 
status of the disease. Furthermore nuclear imaging can be used for treatment monitoring, 
moreover studies in newly diagnosed MM have shown that complete normalization of 
the [18F]-FDG-PET scan before and after ASCT correlates with improved PFS and OS12. For 
relapsing MM patients, similar results have been reported in the diagnostic setting, but no 
conclusive data are available on treatment outcome, which might be related to the small 
number of patients studied. In about 25% of the patients with relapsing MM, no defects are 
shown on [18F]-FDG-PET scan despite the presence of active disease (Table 2A). Comparable 
results have been reported in newly diagnosed MM patients, indicating that a negative [18F]-
FDG-PET scan does not exclude disease activity. Various other tracers can be used to visualize 
MM activity, as shown in Table 2. [11C]-methionine, [11C]-acetate and [11C]-choline are 
promising tracers for detecting skeleton lesions. A drawback of these tracers is the necessity 
of an on-site cyclotron, which prevents wide distribution since it has to be applied shortly 
following production. [18F]-choline, has a longer half-life, is commercially available, and 
could be a good alternative. 
Angiogenesis plays a distinct role in disease progression in MM50-52. Therefore it seems 
promising to use tracers related to this process. Immunohistochemical staining of bone 
marrow biopsies of MM patients show increased MVD, increased VEGF expression by plasma 
cells and increased expression of HIF-2α by the endothelial cells. However no positive scans 
were obtained in proof of principle work, neither with [18F]-FAZA scanning nor with [89Zr]-
bevacizumab PET scanning, despite strongly positive results with [18F]-FDG-PET scanning. 
It has been suggested that HIF-1α increases immediately in response to hypoxia, whereas 










































technical or biological issues, for example due the fact that the bone marrow itself is in a state 
of low hypoxia, which might hamper detection by [18F]-FAZA. 
With immunohistochemical staining we detected high levels of intracellular VEGFa and clear 
alteration in the microvasculature, suggesting that the observed VEGF is secreted by the 
malignant plasma cells. However, this VEGFa could not be visualized by [89Zr]–bevacizumab. 
This is probably due to the limited concentration resulting from rapid binding to plasma cells 
or platelets and the limitations in spatial resolution with the use of 89Zr-tracers. Based on 
these first findings, both [18F]-FAZA and [89Zr]-bevacizumab do not appear to be useful in 
the workup of relapsing MM patients. 
Future perspectives 
Stand-alone MRI is frequently used in the diagnosis of MM, especially for the spine and pelvis. 
PET/MRI appears to be a promising new technique for diagnosis and follow up of myeloma 
patients. It is now possible to perform PET/MRI studies in which metabolic components are 
combined with the anatomic components of the MRI. In MM patients, [18F]-FDG-PET/CT 
has been compared to FDG-PET/MRI. Almost all lesions detected by [18F]-FDG-PET/CT were 
also detected by FDG-PET/MRI58. Further investigation and optimization of the protocol for 
PET/MRI is needed to provide more information about the role of PET/MRI for diagnostic 
purposes and response monitoring in MM. Novel MRI sequences are now available. For 
example, diffusion weighted imaging (DWI) and delayed contrast enhancement (DCE) seem 
to improve the diagnostic properties of MRI in MM patients59,60. Combining PET with these 
novel MRI techniques may be valuable for optimal diagnosis and evaluation of relapsed MM 
activity.
The tracers discussed in this review might also be useful in the radio-immunotherapy setting, 
as described for [68Ga]-Pentixafor. However a drawback might be the negative effects 
on normal hematopoietic cells due to the high expression of CXCR4 on these cells. These 
negative effects on normal hematopoietic cells might be circumvented if this type of radio-
immunotherapy is used in the context of autologous stem cell transplantation. 
In the future radiolabeled daratumumab might be very interesting; preclinical data is 
promising and treatment with daratumumab is well tolerated with encouraging results36,37. 
Also anti-CD138 might be a promising approach38. CD319 also called Signaling lymphocytic 
activation molecule (SLAM) F7 is a receptor present on immune cells including plasma 
cells. The antibody against SLAMF7 is called Elotuzumab. Treatment with this antibody 
demonstrates promising results in relapsing MM patients39. Like anti-CD38 and anti-CD138, 
labeling of this antibody might provide disease information and perhaps to be a new target 
for radio-immunotherapy. Furthermore, labeling with [63Cu]-chelates might also be used in 
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Nuclear imaging is of growing importance in the diagnostic process and follow up of MM 
patients. It provides important information regarding the anatomical localization and the 
metabolic activity of the areas of interest. Combining both information according to uniform 
scoring systems will provide important information for the individual patient but also for the 
comparison of future study protocols. Examples are the five point scaling score shown by the 
Italian group24 and the combined use of TLG and MTV23. 
In conclusion, nuclear imaging is an important tool for diagnostic purposes and response 
monitoring, particularly in relapsing MM patients. Various nuclear tracers have been 
developed to detect bone, bone marrow and extramedullary involvement. In the future, 
these tracers might also be used for treatment monitoring, including detection of minimal 
residual disease. 
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Purpose: Osseous involvement defined by lytic bone lesions is shown by skeletal survey in 
multiple myeloma (MM). This technique has limitations since it detects only lesions with more 
than 30% trabecular bone loss. In addition lesions persist following chemotherapy thereby 
limiting its usefulness at relapsing disease. Alternative techniques to detect new bone lesions 
are somatostatin receptor scintigraphy (SRS) and 18-F-fluorodeoxyglucose positron emission 
tomography ([18F]-FDG-PET) so far predominantly studied in newly diagnosed MM patients. 
Malignant plasma cells can have high expression of somatostatin receptors and an elevated 
metabolic activity. Therefore these techniques might be useful in patients with relapsing MM 
since they are not hampered by preexisting skeletal defects. The purpose of this study is to 
demonstrate which technique is most optimal to detect skeleton lesions in patients with 
relapsing MM. 
Method: In patients with relapsing MM (n=21) three separate methods were used (skeletal 
survey, SRS, and [18F]-FDG-PET) for detecting new skeleton lesions.
Results: 55% of the patients had new lesions on the skeletal survey, (average 1.45 ± 1.76 (range 
0-5), 52% had new SRS-lesions (average 1.43 ± 0.38 (range 0-5) and 71% demonstrated new 
lesions on the [18F]-FDG-PET-scan, (average 4.05 ± 0.9 (range 0-12). The lesions on skeletal 
survey and SRS corresponded with [18F]-FDG-PET. The number of lesions were higher with 
the [18F]-FDG-PET vs. SRS (p = 0.01) and with [18F]-FDG-PET vs. skeletal survey (p = 0.01). 
Conclusions: The results demonstrate that [18F]-FDG-PET is more valuable than skeletal 
survey and SRS to detect disease activity in relapsing MM. 













































Multiple myeloma (MM) is a clonal B-cell disorder characterized by a monoclonal plasma cell 
population in bone marrow, resulting in clinical symptoms of bone pain, hypercalcemia and 
kidney dysfunction1. Osseous involvement is one of the most predominant feature of patients 
with MM; 90% of the patients develop lytic bone lesions. Lytic bone lesions are the result of 
increased bone resorption and reduced bone formation2. The standard method to detect 
bone lesions is skeletal survey. A weakness of this technique is that it can only detect lesions 
that have lost 30% or more of the trabecular bone3. Another limitation is that it cannot be 
used for monitoring treatment results since the lesions persist post-chemotherapy. Therefore 
in relapsing disease skeletal survey examination has limited value unless progressive 
defects are observed. Therefore alternative techniques have been developed to visualize 
disease activity. One of these techniques is the scintigraphy with 111-In-pentetreotide also 
termed somatostatin receptor scintigraphy (SRS). In vitro studies with plasma cell lines 
have shown that somatostatin receptors are highly expressed on malignant plasma cells as 
result of the malignant transformation4. Recently we demonstrated that SRS is a valuable 
tool to detect disease activity in MM patients especially in relapsing MM patients5. Another 
property of malignant cells is the enhanced metabolic activity which can be visualized with 
18-F-fluorodeoxyglucose positron emission tomography ([18F]-FDG-PET). This imaging 
technique might also be useful in patients with relapsing MM since it is not hampered by 
the presence of preexisting skeletal defects6-9. In view of the encouraging results of SRS to 
visualize skeleton abnormities in relapsing MM, we questioned whether the results can 
further be improved by using [18F]-FDG-PET. Therefore we compared skeletal survey and SRS 
with [18F]-FDG-PET in patients with relapsing MM. 
Materials and Methods
Patients
A total of 21 MM patients were prospectively included in this study (table 1). The group 
consisted of 12 man and 9 women with a median age of 61.5 years (range: 48 to 77 years). 
The diagnosis MM was based on the presence of a monoclonal plasma cell population in the 
bone marrow, the presence of a monoclonal Ig protein or elevation of free light chain (FLC) 
in serum (normal range FLC kappa 2.3 – 20.0 mg/l and FLC lambda 4.4 – 32.0 mg/l). Relapse 
after having achieved CR was defined as: 1. Reappearance of paraprotein; 2. More than 5% 
plasma cells in bone marrow; 3. New lytic bone lesions or progression of old lesions; 4. New 
hypercalcemia. Relapse after having achieved PR was defined as: 1. Increase of paraprotein 










































plasma cells in bone marrow with 10%; 4. New lytic bone lesions or progression of old lesions; 
5. New hypercalcemia, according to international guidelines10. 
In all patients a SRS, [18F]-FDG-PET and skeletal survey examination was performed. Patients 
were treated according to ongoing trials or protocols1, 11-13. 17 of 21 patients (81%) were 
treated in the past with autologous stem cell transplantation. Most of the patients were 
treated upfront with three cycles of VAD (vincristine, doxorubicin and dexamethasone) or 
TAD (thalidomide, doxorubicin and dexamethasone). This was followed by peripheral blood 
stem cell collection and transplantation. Treatment schedules used at relapse included 
bortezomib, lenalidomide, thalidomide, dexamethasone and in some cases in combination 
with cyclophosphamide13, 14. At present 10 of the 21 patients are still alive. 
The protocol was approved by the Medical Ethics Committee Groningen, The Netherlands 
and informed consent was obtained from all patients.
Skeletal survey
Each patient underwent a skeletal survey, consisting of radiographs of the skull, humeri, 
femora, whole spine, and pelvis. Conventional radiographs were acquired at 73 kVp and 16 
mAs by using a radiographic imager (MULTIX Swing; Siemens Medical Systems, Chicago, Ill) 
by using a bucky grid. 
Somatostatin receptor scintigraphy
SRS was performed 24 h after intravenous injection of 200 MBq 111-In-pentetreotide. A 
Symbia Siemens double-headed gamma camera (Siemens Medical Systems, Knoxville, TN, 
USA) was used with a matrix of 256x256 and equipped with medium-energy collimator. 
Patients were positioned supine on the imaging table; subsequently 6 views were obtained: 
anterior and posterior of head/neck/thorax, abdomen and the thighs, covering the whole 
body, 10 min/view. SRS images were examined by an experienced nuclear physician using 
visual examination with special attention to the skeleton. Any focal tracer uptake of SRS 
exceeding normal regional uptake was rated as pathological.
[18F]-FDG-PET
All patients had to fast for at least 5 h before undergoing [18F]-FDG-PET. FDG was administered 
intravenously (4-5 MBq/kg). After an uptake period of 60 min, PET emission data were 
acquired from total body, 5 min per bed position. A Biograph mCT scanner was used (Siemens 
Medical Systems, Knoxville, TN, USA). The measured resolution is 2-4 mm in full width at 
half maximum transaxially in the centre of the field of view. For PET data reconstruction 3 
interactions, 21 subsets, with an image size of 256 x 256, zoom 1, was used.
FDG uptake was quantified using the maximal standardized uptake value (SUVmax) analysis 
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blood glucose correction15. The region of interests used in SUV analysis were 3-dimensional 
and were based on the max value within the 50% isocontour boundaries using a Siemens 
workstation (Siemens Medical Systems, Knoxville, TN, USA). The range of regional SUVmax 
values and the average of SUVmax values are mentioned in table 2. 
The SRS and [18F]-FDG-PET were performed within 16 days of each other. [18F]-FDG-PET 
images were examined by an experienced nuclear physician using also visual examination 
with special attention to the skeleton. 
Statistical analysis
P-values were calculated from the data of [18F]-FDG-PET, SRS and skeletal survey using a 
student’s-T-test and Fisher’s exact test. The sensitivity is calculated as the percentage of 
patients with a positive lesion(s) using one of the imaging techniques. 
Results
Patient characteristics are presented in table 1. 57% of patients showed production of 
monoclonal IgG, 24% of IgA and 19% patients only showed production of serum FLC. All 
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Table 2 shows the combined results of skeletal survey and imaging scans. In 71% of the 
patients pre-existing defects were demonstrated on the skeletal survey. New abnormalities at 
relapse were demonstrated in 55% of the patients. The average number of lesions was 1.45 ± 
1.76 (range 0-5). SRS demonstrated abnormal lesions in 52% of the studied patients. In 65% 
of these patients also new lesions were observed on the skeletal survey. The average number 
of lesion on the SRS scan was 1.43 ± 0.38 (range 0-5). The [18F]-FDG-PET showed abnormal 
uptake in 71% of the patients. No diffuse increased bone marrow uptake was noticed in the 
studied patients. The average number of lesion was 4.05 ± 0.9 (range 0-12). The average 
SUVmax was 3.67 with a maximum SUV of 15.8 and a minimum SUV of 0.9. The number of 
lesions was higher with the [18F]-FDG-PET vs. SRS (p = 0.01) and also with [18F]-FDG-PET vs. 
skeletal survey (p = 0.01). No difference was shown in the number of lesions between SRS 
and skeletal survey (p = 1.0). Patients with a positive SRS demonstrated in all cases a positive 
[18F]-FDG-PET scan. 
Table 2. Results of Skeletal survey, SRS, and [18F]-FDG-PET
patient no.





Lesions* Lesions*. Mean SUV 
(range)
1 5 3 5 12 4.5 (1.4 - 15.8)
2 0 4 2 9 2.8 (1.3 – 4.5)
3 0 0 0 3 2.6 (0.9 – 6.5)
4 1 1 3 12 5.1 (0.1 -15.6)
5 0 1 2 3 2.3 (2.2 – 2.4)
6 4 0 0 0 -
7 3 0 0 0 -
8 3 0 0 0 -
9 8 0 5 4 2.5 (1.8 – 3.4)
10 8 5 0 0 -
11 5 5 0 0 -
12 5 nd 1 4 2.2 (1.4 – 3.9)
13 6 3 1 4 5.0 (1.8 – 8.2)
14 8 1 3 4 3.0 (1.7 – 5.0)
15 5 0 3 10 3.2 (1.9 – 6.8)
16 0 1 0 2 2.3 (2.2 – 2.4)
17 2 0 0 5 6.0 (2.3 -12.2)
18 4 3 4 10 3.3 (2.7 – 3.5)
19 3 2 1 2 2.2 (1.7 – 2.6)
20 0 0 0 0 -
21 0 0 0 1 3.2
Legend: n: number; SRS: somatostatin receptor scintigraphy; [18F]-FDG-PET: 18-F-fluorodeoxyglucose 
positron emission tomography; SUV: standardized uptake value; nd: not done; *: number of lesions 










































Table 3. Overall results comparing FDG-PET, SRS and Skeletal survey
18F-FDG PET vs. SRS 18F-FDG PET vs. Skeletal survey
n (%) n (%)
Total 21 (100)  Total 20 (100)
PET pos 15 (71) PET pos 15 (75)
SRS pos 11 (52) Skeletal survey pos 11 (55)
PET > SRS 14 (67)* PET > Skeletal survey 14 (70)*
PET < SRS 1 (5) PET < Skeletal survey 2 (10)
PET= SRS 6 (28) PET = Skeletal survey 4 (20)
Legend: SRS: somatostatin receptor scintigraphy; [18F]-FDG-PET: 18-F-fluorodeoxyglucose positron 
emission tomography; pos: positive lesions; neg: negative lesions; vs.: versus; PET > SRS: patients with 
more lesions found on the FDG-PET than on SRS; PET < SRS: patients with less lesions found on the FDG-
PET than on SRS; PET = SRS: same amount of lesions found on FDG-PET and SRS; * p=0.01.
Table 3 shows the overall results of the comparisons of [18F]-FDG-PET with skeletal survey 
and SRS scans. A representative example for [18F]-FDG-PET versus SRS is demonstrated in 
figure 1. New lesions observed on the skeletal survey corresponded with lesions shown on 
the [18F]-FDG-PET, except for lesions found on the X-skull. In 42% of the patients skeletal 
survey demonstrated new lesions on the X-skull which were not demonstrated on the [18F]-
FDG-PET. Frequently these lesions were single and small (less than 1 cm). The anatomical 
localization of the defects defined by SRS corresponded in general with defects defined by 
[18F]-FDG-PET. In one patient a lesion on the skull was visible on the SRS scan but not on the 
[18F]-FDG-PET. In addition in one patient with an extra-osseous lesion a strong positive [18F]-
FDG-PET (SUVmax 15,6) was demonstrated which was less clear visible on the SRS-scan while 
on the skeletal survey only a slight defect was present.
Remarkable in 6 patients no abnormal lesion could be demonstrated although all patients 
had distinct signs of relapsing disease. No association could be made between the positivity 
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Legend: A, [18F]-FDG-PET scan lesions in the sternum, clavicles, scapula, proximale humeri (both sides), 
thoracic vertebrae, femur, and tibia (on this picture, small lesions were difficult to point out). B, Pictures 
of SRS with lesions in the left proximal humerus and less in the right proximal humerus and the sternum 











































Skeletal survey is the standard method to detect skeletal lesions in patients with MM. In newly 
diagnosed MM patients 50-70% of patients demonstrate osteolytic lesions1. In relapsing 
disease it can be more difficult to demonstrate disease progression due to the presence of 
pre-existing skeleton abnormalities.
New techniques are used to demonstrate in an alternative way disease progression. In 
particular MRI scanning is recommended for detecting osteolytic lesions in the spinal and 
pelvic regions. The disadvantage of the MRI technique is the difficulty to use it for response 
evaluation since it takes 9-12 months before lesions resolve on MRI8, 9. In addition it has 
limitations for detecting bone marrow infiltration in ribs, clavicle and skull. 
In our previous study we showed that SRS scanning is a valuable tool to detect MM activity 
especially in relapsing MM patients5. Apparently high expression of somatostatin receptors 
can be found on malignant plasma cells at relapse which is in line with results obtained 
with plasma cell lines4. In the present study we used also an alternative property of the 
transformed cells i.e. the enhanced glucose uptake by the malignant plasma cells visualized 
by [18F]-FDG-PET scanning. 
So far studies with [18F]-FDG-PET have in particular been performed in untreated MM 
patients demonstrating more positive lesions on the [18F]-FDG-PET scan in comparison to 
skeletal survey in 50% of the patients16. In the present study with patients with relapsing 
MM also the highest number of abnormal hotspots was demonstrated with [18F]-FDG-PET 
compared to skeletal survey and SRS. Apparently accumulation of metabolic active malignant 
plasma cells in the bone marrow visualized by [18F]-FDG-PET do not translate in every case 
in trabecular defects. 
In general the defects on skeletal survey examination were also demonstrated with the [18F]-
FDG-PET except for small, diffuse defects on the X-skull. It has been demonstrated that small 
sub centimeter lesions are difficult to detect with the [18F]-FDG-PET scan7, 16. We observed 
new skeletal survey lesions in 55% of the patients. This number might overestimate the real 
number following last relapse since a number of patients had several relapses and skeletal 
survey was not performed on every occasion. This likely explains also the finding that newly 
defined lesions on the skeletal survey in some patients were in fact old lesions and therefore 
negative on SRS and [18F]-FDG-PET.
[18F]-FDG-PET has become an established imaging modality for the detection of osseous 
lesions in newly diagnosed MM patients and appears to be an independent prognostic 
parameter for overall survival9, 16. In relapsing MM patients only limited studies have 
been performed. Derlin et al demonstrated recently in relapsing MM patients following 
allogeneic stem cell transplantation a positive [18F]-FDG-PET scan in 80% of the patients 
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improvement can likely be obtained by combining [18F]-FDG-PET with low-dose CT scanning 
which will give the advantage to detect more defined lesions in the skeleton but will also 
demonstrate in more detail extramedullary disease. Remarkable in 20% of the patients no 
distinct abnormalities were observed on SRS, [18F]-FDG-PET and skeletal survey despite 
the fact that clinical parameters indicated diffuse and active disease. Apparently malignant 
plasma cell proliferation in these cases is not associated with an enhanced metabolic activity 
as so far detected by [18F]-FDG-PET. Enhanced uptake of [18F]-FDG-PET uptake might be 
related to hypoxia in the bone marrow compartment or to hypoxia in expanding tumor cells. 
Alternatively the activation of the hypoxia pathway might be induced by genetic mutations 
in the plasma cells. Recently we demonstrated that signal transducers and activators of 
transcription 5 (STAT5) up regulates hypoxia inducing factor (HIF)-2 alpha18. Whether 
comparable cellular interactions take place in myeloma cells is unknown but requires further 
study. 
In summary the results demonstrate that [18F]-FDG-PET is more valuable than skeletal survey 
and SRS to detect disease activity in relapsing multiple myeloma. 
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Introduction: Whole body X-ray (WBX) is used for detecting skeleton abnormalities in multiple 
myeloma (MM) patients. An alternative might be [F-18]fluorodeoxyglucose positron emission 
tomography (FDG-PET) which make use of metabolic changes of malignant plasma cells. The 
aim of this study is to demonstrate whether [18F]-FDG-PET is more valuable in relapsing 
MM compared to WBX and to define its prognostic value. In addition 1-α-D: -(5-deoxy-5-
[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ([18F]-FAZA) scan and immunohistochemical 
staining on bone marrow was performed to define whether FDG uptake coincides angiogenesis 
related tumor hypoxia. 
Methods: [18F]-FDG-PET (n=44) and [18F]-FAZA PET (n=5) was performed in patients with 
relapsed MM. Bone marrow biopsies (n=20) were evaluated for hypoxia inducible factors 
(HIF) -1α and -2α, vascular endothelial growth factor (VEGF), glucose transport protein (GLUT) 
1 and 3 and the micro-vessel density (MVD). 
Results: New lesions were more frequently demonstrated on [18F]-FDG-PET than on WBX 
(p=0.000001). [18F]-FDG-PET was not predictive for progression free survival and overall 
survival. Immunohistochemical staining on bone marrow biopsies demonstrated a significant 
increase in MVD and elevated expression of VEGF, HIF-2α and GLUT-3 by the malignant 
plasma cells. However HIF-1α expression and [18F]-FAZA scans were negative.
Conclusion: Our results demonstrate that [18F]-FDG-PET is relevant for diagnostic purposes 
compared to WBX in relapsing MM. The enhanced uptake of [18F]-FDG-PET is likely related to 
the activation of the HIF-2α signaling pathway, but probably independent of hypoxia induced 
signaling in view of the negative findings on both [18F]-FAZA PET and HIF-1α expression.
Keywords: relapsing multiple myeloma, [18F]-FDG-PET, [18F]-FAZA, immunohistochemical 












































Multiple myeloma (MM) is a disease characterized by a monoclonal plasma cell population in 
bone marrow whereby osseous involvement is a predominant feature. In 90% of the patients’ 
lytic bone lesions develop, which is an important cause of morbidity1. Lytic bone lesions are 
the result of increased bone resorption and reduced bone formation2. Whole body X-ray 
(WBX) is the method of choice for detecting skeleton abnormalities. This technique has several 
limitations such that it can detect only lesions that have lost more than 30% of the trabecular 
bone3. Furthermore the value in relapsing disease is limited because lesions persist after 
treatment so it cannot distinguish old vs. new active skeleton lesions. Therefore alternative 
techniques have been developed to visualize disease activity. 18-F-fluorodeoxyglucose 
positron emission tomography ([18F]-FDG-PET) uses the enhanced metabolic activity of cells 
to visualize the abnormal lesions4. In newly diagnosed MM patient [18F]-FDG-PET detects 
more lesions compared to WBX; furthermore, a positive [18F]-FDG-PET scan is of prognostic 
value5. This imaging technique may also be useful in patients with relapsing MM since it is not 
hampered by the presence of preexisting skeletal defects and visualizes areas of enhanced 
metabolic activity6-8. Indeed, in our previous study we demonstrated that [18F]-FDG-PET is 
a valuable tool for detecting MM activity in patients with relapsing MM9. In view of these 
encouraging results we extended the number of included patients having a [18F]-FDG-PET 
and a skeletal survey in the work up of relapsing MM to evaluate whether [18F]-FDG-PET 
indeed detects more lesions in patients with relapsing MM and has a prognostic value in the 
relapse setting of MM as well. 
The enhanced metabolic activity defined by [18F]-FDG-PET could be related to hypoxia and 
the subsequent increased protein expression of hypoxia inducible factors (HIF) 1α and 2α, 
which can trigger the vascular endothelial growth factor (VEGF) pathway and stimulate 
angiogenesis10,11. Previous studies have shown that angiogenesis defined by increased micro-
vessel density (MVD) is highly correlated with progressive disease in MM12. Recently new 
scanning methods have been developed for demonstrating in vivo tumor hypoxia. The PET 
tracer hypoxia, 1-α-D:-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ([18F]-
FAZA), has been shown to accumulate in tumor hypoxia. In a study performed by Postema 
et al., 50 patients with different types of malignancy (solid as well as hematologic), tumor 
hypoxia could be demonstrated in 46% of the patients13. 
Based on these findings we studied in vitro hypoxia related proteins including HIF 1α and 
2α, VEGF and other hypoxia related proteins such as glucose transporter (GLUT) 1 and -3 
expression on bone marrow biopsies of MM patients and determined MVD. In addition, in 
vivo [18F]-FAZA scans were performed in these patients to demonstrate whether tumor 
hypoxia can also be visualized in vivo in MM patients and whether this corresponds with 












































A total of 44 MM patients were prospectively included in this study. Approval for the study 
was obtained from the local medical ethical committee. The diagnosis MM was based on 
the presence of a monoclonal plasma cell population in the bone marrow, the presence of a 
monoclonal immunoglobulin protein or elevation of free light chain (FLC) in serum (normal 
range FLC kappa 2.3 – 20.0 mg/l and FLC lambda 4.4 – 32.0 mg/l) and the presence of 
one or more of the following related organ or tissue impairments; lytic bone lesion, renal 
involvement, hypercalcemia or anemia. Relapse MM after having achieved CR was defined 
as follows: 1. reappearance of paraprotein; 2. more than 5% plasma cells in bone marrow; 3. 
new lytic bone lesions or progression of old lesions; 4. new hypercalcemia. Relapse MM after 
having achieved PR was defined as follows: 1. increase of paraprotein with more than 25%; 2. 
increase of urine paraprotein with more than 25%; 3. increase of plasma cells in bone marrow 
with 10%; 4. new lytic bone lesions or progression of old lesions; 5. new hypercalcemia, 
according to international guidelines14. 
In all patients with relapsing MM in our institute, a [18F]-FDG-PET scan was performed. 
A skeletal survey examination was performed in 38 patients. A subgroup of patients with 
a positive [18F]-FDG-PET scan result were randomly chosen to undergo an [18F]-FAZA. 
Patients were treated according to ongoing trials or protocols15-17. Of 44 patients, 37 (75%) 
were previously treated with autologous stem cell transplantation. Most of the patients 
were treated upfront with three cycles of induction with VAD (vincristine, doxorubicin and 
dexamethasone), TAD (thalidomide, doxorubicin and dexamethasone) or PAD (bortezomib, 
adriamycin and dexamethasone). This was followed by peripheral blood stem cell collection 
and transplantation. Treatment schedules used at relapse included bortezomib, lenalidomide, 
thalidomide, dexamethasone and in some cases in combination with cyclophosphamide or 
melphalan. At last follow up 26 of the 44 patients are alive. 
Response to treatment was measured using the standard criteria, although not all patients 
underwent a repeated bone marrow biopsy to establish complete response. CR is defined as 
no m-protein or FLC present and normal bone marrow, very good partial response (VGPR) is 
defined as more than 90% reduction in m-protein or FLC. PR is defined as a more than 50% 
reduction in m-protein or FLC and progressive disease as an increase in m-protein or FLC with 
more than 25%14. 
Immunohistochemistry for MVD, VEGF-A, HIF 1α and 2α and GLUT-1 and -3
The expression of angiogenesis and hypoxia related features was examined by 
immunohistochemical staining on bone marrow biopsies (n=20). After fixation in 10% neutral 
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containing 10% (v/v) acetic acid and 10% formalin (v/v; 3.6% formaldehyde) for 1 or 2 days. 
Than the bone marrow was paraffin embedded and cut in sections of 4 µm and stained 
as follows. Slides were dewaxed and rehydrated in graded alcohol solutions. Endogenous 
peroxidase activity was blocked with hydrogen peroxide. Antigen retrieval was done heat-
induced with the microwave, expect for the VEGF staining were antigen retrieval was done 
with protease 0.1%. Slides were than incubated with the primary antibody for GLUT-1 (rabbit 
polyclonal 07-1401, Millipore USA; diluted 1:750), GLUT-3 (rabbit polyclonal ab15311, Abcam 
UK; diluted 1:100), HIF-1α (mouse monoclonal clone 54/HIF-1α BD Biosciences; diluted 1:70) 
HIF-2α (mouse monoclonal ab8365, Abcam; diluted 1:200) and VEGF-A (rabbit polyclonal 
sc-152, Santa Cruz USA; diluted 1:50). Blood vessels were visualized with a CD34+ antibody 
(mouse monoclonal QBEnd 10, Dako, Copenhagen, Denmark). The slides were washed 
with PBS and after that incubated with a rabbit anti mouse or goat anti rabbit horse radish 
peroxidase conjugated as secondary or tertiary antibody. For the VEGF staining streptavidine 
peroxidase was used as a tertiary antibody. The chromogenic reaction was performed with 
diaminobenzidine for 12 min and after that sections were counterstained with haematoxylin. 
Finally, the slides were dehydrated and mounted. 
The intensity of staining was analyzed semi-quantitatively. The percentage of positive plasma 
cells was counted according the following scoring system: no visibility, 10-30% positive, 30-
50% positive, 50-80% positive and more than 80% positive plasma cells18. The vessel count 
was measured using light microscopy in areas of the slide containing highest numbers of 
blood vessels per selected area (hotspot). After the hotspots were identified, the total 
number of vessels per selected image was counted at 400 magnifications. At least five fields 
were counted for each section and the true vessel number was expressed as the mean of 5 
counts19. 
Skeletal survey
Each patient underwent a whole body X-ray survey, consisting of X-skull, X-humeri, X-femora, 
X-whole spine, X-pelvis. Conventional radiographs were acquired at 73 kVp and 16 mAs by 
using a radiographic imager (MULTIX Swing; Siemens Medical Systems, Chicago, Ill) by using 
a bucky grid. 
[18F]-FDG-PET
All patients had to fast for at least 5 h before undergoing [18F]-FDG-PET. FDG was administered 
intravenously (4-5 MBq/kg). After an uptake period of 60 min, PET emission data were 
acquired from total body, 5 min per bed position. A Biograph mCT scanner was used (Siemens 
Medical Systems, Knoxville, TN, USA). The measured resolution is 2-4 mm in full width at 
half maximum transaxially in the center of the field of view. For PET data reconstruction 3 










































FDG uptake was quantified using the maximal standardized uptake value (SUVmax) analysis 
in all patients. A standardized protocol for quantification of SUVmax was used, including 
blood glucose correction20. The region of interests used in SUV analysis were 3-dimensional 
and were based on the max value within the 50% isocontour boundaries using a Siemens 
workstation (Siemens Medical Systems, Knoxville, TN, USA). 
The number, size, localization and SUVmax of focal lesions were recorded. The [18F]-FDG-
PET scan was either negative with no focal lesions or positive with focal lesions. In addition, 
definition by Zamagni et al was used, defining PET positivity as more than 3 lesions or SUVmax 
> 4.25.
The skeletal survey and [18F]-FDG-PET were performed within a month of each other. 
[18F]-FDG-PET images were examined by an experienced nuclear physician using also visual 
examination with special attention to the skeleton. 
[18F]-FAZA
Procedures for good-manufacturing-practice production of the hypoxia tracer [18F]-FAZA 
have been developed previously. The synthesis of [18F]-FAZA was optimized using a Micro 
Fluid Chemistry Module (Advion). The routine production was performed using a robot 
system (Zymark). Briefly, the precursor (2 nitro imidazole) for labeling [18F]-FAZA was reacted 
with dried 18F/K222 complex in dimethyl sulfoxide and thereafter deprotected with 0.1 M 
NaOH. After high-performance liquid chromatography purification of the reaction mixture, 
[18F]-
FAZA was formulated using an Oasis HLB plus cartridge. The final sterile solution was 
analyzed using high-performance liquid chromatography and released for administration to 
the patient.
[18F]-FAZA PET scans were performed on the same mCT camera as the [18F]-FDG images 
according to local standard operating procedures for [18F]-FAZA PET scans. Patients were 
injected with 370 MBq intravenously. After a waiting period of 120 min, a scan was obtained 
from the midthigh to the brain and analyzed using the previous-mentioned research 
workstation. [18F]-FAZA SUVmax was quantified in the same way as [18F]-FDG SUVmax, 
including correction for the partial-volume effect. The median time interval between [18F]-
FDG PET and [18F]-FAZA PET was 21 days (range 1-51). The data were reconstructed with 
time-of-flight, high-definition, ordered-subsets expectation maximization using 3 iterations, 
21 subsets, and a 5-mm gaussian postprocessing filter and had a spatial resolution of 2.04 × 
2.04 × 2 mm.
Statistical analysis
Difference between the amount of lesions between WBX and [18F]-FDG-PET were calculated 
from the data using a Wilcoxon signed ranks test. Survival was calculated using the method 
of Kaplan and Meier and compared by log rank test. Correlation was calculated using a 












































This study included 44 patients. The group consisted of 27 men and 17 women with a median 
age of 62.5 years (range 48 to 78 years). Median number of prior treatment regimens was 
3.5 (range 2-12). Patient characteristics are presented in table 1. Fifty-five percent of patients 
showed production of monoclonal IgG, 8% of IgA and 35% patients only showed production 
of serum FLC. 
Table 1: Patient characteristics
Characteristic (n = 44) Number %
Age (years)
median 62




no of prior treatment regimens
median 3.5





FLC only 17 35
% plasma cells bone marrow at relapse MM
No bone marrow 4 10
1-Oct 22 45
Oct-30 17 35
> 30 5 10
Type of prior treatment
Autologous stem cell transplantation 42 86




Low dose melphalan 14 29
Legend: FLC; free light chain. MM; multiple myeloma.
During the follow up 5 patients experienced two episodes of relapse. For each relapse [18F]-
FDG-PET was performed. Not in all cases a skeletal survey was performed in combination 
with [18F]-FDG-PET. In total 49 [18F]-FDG-PET scans were performed and 38 skeletal survey 
examinations. In 79% of the patients pre-existing defects were demonstrated on the skeletal 










































number of skeletal lesions on X-ray was 0 (range 0-7). The [18F]-FDG-PET showed abnormal 
uptake in 82% of the patients. No diffuse increased FDG uptake in bone marrow was noticed 
in the studied patients. The median number of FDG lesions was 4 (range 0-22). The average 
SUVmax was 5.4 with a highest SUVmax of 14.1 and a lowest SUVmax of 1.7. The number of 
lesions was significantly higher with the [18F]-FDG-PET vs. skeletal survey (p = 0.000001). 
One patient had a lesion in the skull, not detected on [18F]-FDG-PET. One other patient had 
several small lesions (1 cm or smaller) in pelvic and femur also not detected with [18F]-FDG-
PET. None of the patients received treatment before the skeletal survey and [18F]-FDG-PET. 
All other lesions defined by the skeletal survey were confirmed on the [18F]-FDG-PET. In 
addition, in 5 patients extra-osseous lesions were detected with strong positive FDG avid 
lesions (median SUVmax 9.7). None of these lesions were demonstrated on plain X-ray. For 
9 patients no abnormal lesions could be demonstrated on both [18F]-FDG-PET and WBX 
although all patients had distinct signs of relapsing disease. 
Treatment results were available for all 44 patients. CR was obtained in 13 (27%) of the 
patients, VGPR in 6 (12%) patients, PR in 13 (27%) patients and progressive disease in 13 
(27%) patients. For 3 patients it was not possible to measure treatment response, 1 patient 
was lost during follow up, 1 patient died due to another cause and for 1 patient the follow up 
interval was too short. Median follow-up was 14 months (range 2-49). Median progression 
free survival (PFS) was 11.7 months (range 2-43). For patients reaching a CR the median 
PFS was 16 months compared to 5.3 months for patients with progressive disease (p= 
0.00001). Overall survival was not reached for patients with CR vs. 8 months for patients with 
progressive disease (p = 0.000001). 
In 12 patients [18F]-FDG-PET was performed after chemotherapy treatment. Nine patients 
had responsive disease with decrease in the number of lesions according to the [18F]-FDG-
PET. Of 9 patients, 3 (33%) had a CR on the [18F]-FDG-PET. Two patients had stable disease 
and 1 patient had progressive disease. On the [18F]-FDG-PET before treatment there were 
median 7.5 lesion (range 1-22) and after treatment 3 lesions (range 0-10). The median SUV 
max declined from 5.5 (range 3.3-9.4) to 2.27 (range 0-4.6) (p=0.003). Response observed 
with [18F]-FDG-PET was comparable to clinical response. 
Overall, [18F]-FDG-PET findings were not predictive for PFS (p =0.30) and OS (p=0.33) and 
also when PET positivity was defined as more than 3 lesions or SUVmax > 4.25. Figure 1A and 
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------- FDG-PET pos 
Legend: The correlation between [18F]-[18F]-FDG-PET outcome and progression free survival.
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Immunohistochemical staining on bone marrow biopsies (n=20) with the CD34 monoclonal 
antibody demonstrated an increased MVD scoring of median 13.5 (range 3-200) vs. 3.5 on 
normal bone marrow21. The MVD was particular high when clusters of plasma cells were 
present. In 80% of the bone marrow biopsies more than 50% of the plasma cells were positive 
for VEGF-A. The staining for the GLUT demonstrated that 10% of the biopsies showed more 
than 50% of the plasma cells positive for GLUT-1 and in 55% of the biopsies for GLUT-3. A clear 
distinction was observed for HIF-1α and HIF-2α; no staining for HIF-1α was demonstrated 
on plasma cells although the surrounding endothelial cells demonstrated a distinct positive 
staining, while in 85% of the samples more than 50% of the plasma cells were positive for 
HIF-2α. Table 2 shows the results of immunohistochemistry combined with the results of the 
[18F]-FDG-PET and treatment outcome. Figure 2 provides the results of the staining from 1 
patient. MVD was the only factor that correlated with [18F]-FDG-PET positivity (p = 0.03). 
The expression of VEGF (p = 0.67), HIF-2α (p=0.33) or GLUT-3 (p =0.50) was not predictive for 











































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2: Immunohistochemical staining for GLUT-1 and 3, HIF-1α and HIF-2α, VEGF and MVD
 
 
Legend: Immunohistochemical staining for A:GLUT-1, B:GLUT-3, C:HIF-1α, D:HIF-2α, E:VEGF and F:MVD. 
GLUT; glucose transporter, HIF; hypoxia inducible factors, VEGF; vascular endothelial growth factor, 
MVD; micro-vessel density.
Five randomly chosen patients (4 male and 1 female) underwent an [18F]-FAZA PET scan. All 
five patients had a positive [18F]-FDG-PET scan. They received no treatment before the [18F]-
FAZA scan. They had a median of 0 (range 0-1) lesions on the WBX and a median of 7 (range 
2-15) lesions on the [18F]-FDG-PET. The median SUVmax was 9.4 (range 4.2-13.6). No lesions 
were demonstrated on [18F]-FAZA PET. Figure 3 demonstrates a patient with clear [18F]-FDG-
PET positivity of a large extramedullary lesion but without uptake on [18F]-FAZA PET.
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Legend: [18F]-FDG-PET and [18F]-FAZA image of patient (number 16 in table 2) with progression of 
MM. Large extramedullary and multiple ossal lesions are visible on the [18F]-FDG-PET scan (left scan). 
No lesions were visible on the [18F]-FAZA scan (right scan).
Discussion
Skeletal survey is the standard method for the detection of skeletal lesions in patients with 
MM. In relapsing disease measurement of disease progression is difficult to assess with this 
method because of the presence of pre-existing skeleton abnormalities. New techniques 
are therefore explored to demonstrate disease progression. In particular, MRI scanning 
is recommended for detecting osteolytic lesions in the spinal and pelvic regions. The 
disadvantage of this technique is the difficulty to use it for response evaluation since it takes 
9-12 months before lesions resolve on MRI8. In addition, it has limitations for detecting bone 
marrow infiltration in ribs, clavicle and skull3. 
In the present study we used the property of enhanced metabolic activity shown by increased 
glucose uptake by the malignant plasma cells visualized on [18F]-FDG-PET. Thus far studies 
with [18F]-FDG-PET have been performed in untreated MM patients, demonstrating more 










































patients with relapsing MM also demonstrated a higher number of lesions with FDG-PET as 
compared with WBX. This is probably due to the fact that over 30% of the trabecular bone 
must be lost before osteolytic lesions are visible on WBX3. 
In general the lesions found on WBX were also demonstrated with [18F]-FDG-PET, except 
for small, diffuse defects. It has been demonstrated that small lesions, < 1 cm, are difficult 
to detect with [18F]-FDG-PET23, due to limited resolution of the PET camera. We observed 
new skeletal survey lesions in 42% of the patients. This number might overestimate the real 
number of skeletal lesions after the last relapse because a number of patients had several 
relapses and skeletal survey was not performed on every occasion. On the other hand, 
extramedullary MM will be missed on WBX and can be appropriately diagnosed with [18F]-
FDG-PET4.
[18F]-FDG-PET has become an established imaging modality for the detection of osseous 
lesions in newly diagnosed MM patients and seems to be an independent prognostic 
parameter for overall survival5. In relapsing MM patients only limited studies have been 
performed. Derlin et al, demonstrated in relapsing MM patients following allogeneic stem 
cell transplantation a positive [18F]-FDG-PET scan result in 80% of the patients24, which 
is comparable to our patients following autologous stem cell transplantation. Overall, we 
noticed that [18F]-FDG-PET provides more information than does WBX for detecting skeleton 
lesions in relapsing MM patients.
[18F]-FDG-PET has prognostic value for the treatment results in newly diagnosed MM 
patients5. However, in this cohort of relapsing MM we could not demonstrate the prognostic 
significance for [18F]-FDG-PET positivity. This might be due to the great variability in the 
number of relapses and prior treatment regimens. Median PFS was 11.7 months (range 
2-43), which is comparable to other studies in patients with relapsing disease25. The most 
important factor was the response to treatment, patients reaching CR having a better PFS 
and OS (p=0.00001).
To study in greater detail the cause of the enhanced uptake of [18F]-FDG-PET in MM, we 
studied different parameters that are linked and may influence FDG uptake activity, such as 
tumor hypoxia. The PET tracer [18F]-FAZA makes use of this condition. Two-nitroimidazole 
compounds undergo reduction under hypoxic conditions, forming highly reactive oxygen 
radicals. This binds to macro-molecules inside the cell. When labeled with a radioisotope, this 
can be visualized with a PET-scanner. [18F]-FAZA has been used in patients with solid tumor 
like head and neck cancers and non-small cell lung cancers to detect tumor hypoxia26, 27. [18F]-
FAZA scan was positive in two third of the head and neck cancer patients and in all non-small 
cell lung cancer patients26, 27. In our study we evaluated the regional uptake of [18F]-FAZA in 
patients with relapsing MM with a positive [18F]-FDG-PET scan result. However, in none of 
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It is well known that bone marrow of MM patients reveal higher MVD and increased VEGF 
expression12. The expression of VEGF can be regulated by hypoxia inducible factors like HIF-
1α and HIF-2α. In contrast to the study of Giatromanolaki et al11 who demonstrated that 
33% of the MM patients stained positive for HIF-1α, no HIF-1α staining of plasma cells was 
demonstrated in our patients. In addition we observed a low GLUT-1 expression, which is in 
line with the results of the HIF-1α staining since GLUT-1 is a downstream target of HIF-1α. 
The negative [18F]-FAZA scan result corresponds also with these findings. However HIF-2α 
expression was demonstrated in a high number of samples in conjunction with an increase 
in MVD and elevated expression of VEGF, suggesting that the HIF signaling pathway was 
activated. The number of MVD also correlated with the positivity on [18F]-FDG-PET. In solid 
tumor different expression patterns of HIF-1α and HIF-2α are described, suggesting different 
roles for both factors. It has been proposed that HIF-1α increases directly in response to 
hypoxia, while HIF-2α is responsive during prolonged period of hypoxia28. However, expression 
of HIF or VEGF is not synonymous with tumor hypoxia. Alternative pathways can be activated 
due to oncogene activation or mutations that trigger the expression of HIF. For example, it has 
been shown that signal transducer and activator of transcription 5 (STAT-5) can activate the 
expression of HIF-2α. STAT-5 can be activated by several cytokines and it induces expression 
of several target genes, including HIF-2α29. Whether STAT-5 plays an important role in multiple 
myeloma is not extensively studied but this could explain the observed difference in uptake 
between [18F]-FDG-PET and [18F]-FAZA. 
In summary, our results demonstrate that in relapsing MM patients [18F]-FDG-PET is highly 
relevant for diagnostic purposes compared with WBX, but has limited value as prognostic 
parameter. The enhanced uptake of [18F]-FDG-PET is likely related to the activation of the HIF 
signaling pathway but not related to hypoxia in view of the negative findings on [18F]-FAZA 
PET.
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Combination therapy for longer periods but at low dose might be an effective and tolerable 
manner to treat patients with relapsed multiple myeloma (MM). We used bortezomib, 
dexamethasone and low-dose oral cyclophosphamide as an induction regimen, followed by 
one year of maintenance consisting of bortezomib and cyclophosphamide. 
Relapsed MM patients were treated with six cycles of bortezomib twice weekly, 
cyclophosphamide 50 mg daily, and dexamethasone. Maintenance therapy was given for 
one year. Primary endpoints were toxicity during re-induction and maintenance therapy. 
Secondary endpoints were response to treatment and progression-free (PFS) and overall 
survival (OS).  
We included 59 patients. Myelosuppression and neuropathy were the most common side 
effects. Median follow up was 27.1 (0.46–54.4) months with an overall response of 71%, and 
a very good partial response or more of 33%. During maintenance, improved responsiveness 
was observed in 19% of the patients. The median PFS was 18.4 months (range 0.13–43.5) and 
the median OS was 28.1 months (range 0.13–54.4). 
In conclusion, our study demonstrates that treatment with bortezomib, dexamethasone and 
low-dose cyclophosphamide is an effective and manageable regimen. Adding one year of 
maintenance was feasible, with limited side effects and an increased response rate.












































The treatment of Multiple myeloma (MM) has changed substantially during the last decade. 
Several novel agents have become available for treating MM, such as bortezomib, lenalidomide 
and thalidomide. First-line treatment for younger patients consists of chemotherapy, including 
novel agents, followed by autologous stem cell transplantation (ASCT). Patient ineligible for 
ASCT are treated with a combination of melphalan, prednisolone and a novel agent. Following 
the introduction of these new regimens, the overall survival (OS) improved considerably: the 
5-year OS for younger MM patients is now 70%, and that for older patients is 41%1. 
However, for patients with relapsing or refractory MM, no standard treatment is available. 
Choice of re-treatment depends on factors such as age, performance status, results of prior 
treatment regimens and presence of polyneuropathy2,3. Bortezomib is used in the upfront 
and relapse setting. Adding bortezomib to conventional cytotoxic drugs improves the 
efficacy in newly diagnosed MM patients4,5. In relapsed MM patients, the combination of 
dexamethasone and bortezomib was superior compared to high dose dexamethasone alone6. 
Main site effects were mild myelosuppression and peripheral neuropathy. Considering the 
favorable results of bortezomib maintenance in upfront patients, maintenance therapy might 
also be an option in relapsed patients4. 
Combination therapy in the upfront and relapse setting is a very effective strategy because 
it provides the opportunity to trigger different cell death pathways initiated by the various 
agents. Clinically, this is translated in an improved progression free survival (PFS) compared to a 
single agent treatment. A potential component of combination therapy is cyclophosphamide. 
It has a well-known anti myeloma activity without cross resistance to melphalan7. Low dose of 
continuous oral cyclophosphamide, also called metronomic scheduling, minimizes toxic side 
effects and eliminate the obligatory rest periods, thus resulting in continuous suppression 
of the malignant clone8. This also allows it to be used for longer periods, for example in the 
setting of maintenance therapy. When combined with thalidomide without dexamethasone, 
oral cyclophosphamide is effective and well tolerated for relapsed MM8.
In the present study, we determined the feasibility of combination therapy in relapsing 
bortezomib-naïve myeloma patients using bortezomib, dexamethasone and low dose 
cyclophosphamide, followed by one year of maintenance with bortezomib and low-dose 
cyclophosphamide. The primary endpoint of the study was toxicity during re-induction and 
in maintenance therapy. Secondary endpoints were response to treatment and progression-












































Eligible for inclusion were MM patients with relapsed or primary refractory disease after 
initial treatment. Relapsed MM was defined according to international guidelines9. These 
guidelines include the following criteria: 1. An increase of 25% or more from baseline serum 
m-protein or bence jones proteinuria, or a similar increase in the difference between involved 
and uninvolved free light chain (FLC) levels (in patients without measurable m-protein or 
Bence Jones proteinuria in urine); 2. More than 10% plasma cells in bone marrow; 3. New 
lytic bone lesions or progression of old lesions; 4. New hypercalcemia. 
Patients having prior treatment with bortezomib were excluded. Minimum age for enrollment 
was 18 years, with no upper limit. Patients had to have an absolute neutrophil count of at 
least 1.0 x 109/l and platelets more than 75x109/l. Patients with pre-existent peripheral 
neuropathy (grade 2 or more according to National Cancer Institute Common Toxicity Criteria 
(NCI CTC) version 3.0), uncontrolled infections or uncontrolled medical or psychiatric illnesses 
were not eligible.
The study was conducted in accordance with the ethical principles of the declaration 
of Helsinki, and the study protocol was approved by the local ethics committee at each 
participating center. Written informed consent was obtained from all patients.
Treatment
Patients were treated with the combination of bortezomib, cyclophosphamide and 
dexamethasone. The first three cycles of 21 days each consisted of bortezomib (1.3 mg/m2) 
at day 1, 4, 8 and 11, cyclophosphamide 50 mg daily, and 20 mg dexamethasone at day 1, 2, 
4, 5, 8, 9, 11 and 12 followed by three cycles of 35 days each of bortezomib 1.6 mg/m2 (day 
1, 8, 15 and 22), cyclophosphamide 50 mg daily and dexamethasone 20 mg at day 1, 2, 8, 9, 
15, 16, 22 and 23. The protocol was amended on 1 February 2012, which allowed bortezomib 
to be administered subcutaneously. Before the amendment all bortezomib was administered 
intravenously. 
Patients with partial or complete response after six cycles of treatment then began 
maintenance therapy consisting of bortezomib 1.3 mg/m2 every two weeks and a daily dose 
of 50 mg cyclophosphamide for one year. Treatment was withheld in case of neutropenic 
fever, hematological toxicity NCI CTC grade 4 or grade ≥ 3 non-hematological toxicity. Once 
toxicity was resolved, treatment with bortezomib and cyclophosphamide was resumed at a 
25% reduced dose. Patients were given prophylactic treatment for pneumococcus infection 
and anti-fungal prophylaxis according to local protocols. In addition, prophylactic treatment 
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Evaluation of patients and criteria for response
The pre-treatment evaluation included whole blood cell count, biochemical tests for renal 
and liver functions and immunofixation of blood and urine. Bone marrow aspiration was 
conducted for cytology to determine the percentage of plasma cells. During treatment, 
blood cell count and biochemical tests for liver and kidney function were done every cycle. 
Response evaluation with M-protein or FLC were done every second cycle. Bone marrow 
aspiration was repeated after 3 and 6 cycles. Response to treatment was defined using the 
standard criteria. 
Complete response (CR) was defined as no M protein, a normal FLC ratio and < 5% plasma 
cells in the bone marrow. Very good partial response (VGPR) was defined as more than 90% 
reduction in M protein or bence jones proteinuria, or serum and urine M protein detectable 
by immunofixation but not on electrophoresis. Partial response (PR) was defined as a more 
than 50% reduction in M protein, or in case no M protein was initially present, by a 50% 
reduction in the difference between involved and uninvolved FLC levels. Progressive disease 
was defined as an increase in M protein or in the difference between involved and uninvolved 
FLC levels with more than 25%9. Minimal response (MR) was defined as a decrease in 
M protein, but less than 25%.
Statistical analysis
This study has been designed to explore the feasibility of bortezomib combined with 
cyclophosphamide and dexamethasone. In a historical control group treated with thalidomide 
and cyclophosphamide, 65 % of the treated patients had a complete or partial response8. 
Based on an expected response rate of 80%, we determined that a sample size of 66 patients 
would provide, at an alpha of 5% and with a power of 90%, that the response rate of treatment 
including bortezomib is higher than 65%. Assuming that 10% of the included patients is 
ultimately not assessable for response, the sample size is calculated at 73 patients. Due to 
the fact that during inclusion time the first line treatment regimens switched to bortezomib 
(bortezomib adriamycin and dexamethasone and melphalan, bortezomib and prednisone) it 
became very difficult to included bortezomib-naïve patients in the last year. For this reason 
the study was ended at 60 patients. 
Toxicity was evaluated only in patients who actually started combination treatment with 
bortezomib, cyclophosphamide and dexamethasone. The incidence of side effects and 
infections were scored according to NCI CTCAE (Common Terminology Criteria for Adverse 
Events) version 3.0. Adverse effects of grade 3 or higher were scored at every cycle and 
cumulatively. Side effects were separated into hematological and non-hematological 
events. Progression-free survival (PFS) was defined as the time from registration to disease 
progression, date of death from any cause or the date of last contact for patients still alive 










































registration to the date of death from any cause or the date of last contact for patients still 
alive at study closure, whichever occurred first. Intention-to-treat analysis was conducted for 
the assessment of PFS and OS, using the Kaplan-Meier method. Response duration, defined 
as the time between best response and disease progression, was estimated by strata of best 
achieved response. Analyses were performed using the STATA software package, version 13.1 
for Windows (Stata Corporation LP, College Station, TX, USA).
Results
Patient characteristics
Between April 2009 and June 2013, 61 MM patients were enrolled in the study. Of this 
group, two patients were excluded due to amyloidosis and missing informed consent. Patient 
characteristics are shown in Table 1. Median age was 69 years (range 46-86), and 70% of the 
patients were in first relapse. The upfront treatment consisted mainly of thalidomide-based 
and vincristine-based chemotherapy; 40% of the patients had been treated with ASCT. Most 
of the patients (63%) had an IgG M protein, 17% had an IgA M-protein, and 17% had free light 
chain disease only. Bone marrow aspirate showed a median of 28% (range 2–99) of plasma 
cells. Peripheral neuropathy (PNP) grade 1-2 before start of the study was seen in 27% of the 
patients.
Treatment 
All 6 cycles of induction chemotherapy could be given to 49% of the patients. Premature 
discontinuation before starting maintenance therapy was due to toxicity (30%), progressive 
disease (8%), death (8%) or other reasons (5%). Maintenance treatment was started in 47% 
of the patients, while 27% did not continue with maintenance therapy because of progressive 
disease. One patient was treated with an allogenic stem cell transplantation after finishing 
6 cycles of induction therapy. Median duration of maintenance treatment was 9.5 months 
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Table 1. Patient characteristics (n=59)
Characteristic Patients (%)

















Light chain disease 17
Unknown 3




Toxicity was evaluated in 55 patients. Toxicity CTC grade ≥ 3 are shown in Table 2. 
Myelosuppression was the most common side effect, occurring predominantly during the 
first 3 cycles of chemotherapy, with NCI-CTC grade 3-4 in 18% of the patients (n = 10). For a 
number of these patients adverse events were reported during different cycles of treatment. 
Dose reduction due to myelosuppresion was required in 13% of the patients, resulting in 
discontinuation of treatment in 1 patient. PNP grade 3-4 was observed in 15% of the patients 
(n=8), of whom 7 received bortezomib intravenously. At the start of the study 15 patients 
already had grade 1 or 2 PNP, (mostly due to prior treatment with thalidomide), of them only 
2 developed grade 3 PNP. In total 13% of the patients developed grade 3 PNP and 2% of the 
patients had grade 4 PNP. The grade 3 PNP or more was observed in two patients during the 
first 3 cycles with twice weekly bortezomib while in 6 patients it was noticed during cycles 
4-6 with once weekly bortezomib. Dose reduction was required in 12% of the patients (n=7), 
and 10% of patients (n=6) discontinued treatment due to PNP. One patient directly stopped 










































toxicity was observed in 25% of the patients, including infections (n=2) and myelosuppression 
(n=2). One patient stopped maintenance treatment due to toxicity. Patients died mainly 
because of progressive disease (n = 21), or due to infectious complications (n=4), allogeneic 
stem cell transplantation (n=1), or unrelated causes (n=5). 
No secondary malignancies were demonstrated during treatment. During follow-up one 
patient developed a myelodysplastic syndrome and one patient had a basal cell carcinoma of 
the skin while none of the patients developed bladder carcinoma. 
Table 2. Toxicity CTC grade ≥ 3 cumulative over all reinduction cycles 
Adverse event CTC grade 3 CTC grade 4 
n % n %
Anemie 2 4 0
Leukocytopenia 8 15 0
Thrombocytopenia 12 22 6 11
Infection 4 7 3 5
Herpes Zoster 0 0
Bleeding 0 0
Neuropathy 7 13 1 2
Dizziness 1 2 0
Fatique 3 5 0
Constipation 1 2 0
Nausea 1 2 0
Diarrea 1 2 0
Gastro-intesinal problem 2 4 0
Musculair/soft tissue 1 2 0
Renal failure 0 0
Liver/pancreas 1 2 0
Endocrine 0 0
Vasculair events 1 2 0
Hypertension 3 5 0
Metabolic/laboratory 5 9 1 2
Venous thromboembolic disease 0 0
Skin 0 0
Pain bone 5 9 2 4
Pain other 2 4 0
Efficacy
After a median follow up of 27 months (range 0.46-54.4), the overall response rate was 72%, 
consisting of 7% CR, 26% VGPR, 33% PR and 6% MR. Stable disease was observed in 14% of 
the patients. For 14% of the patients response evaluation was not performed due to incurrent 
death or no measurements preformed. During the maintenance phase an improvement in 
responsiveness was observed in 19% of the patients while 54% of patients had no change 
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treatment. The median PFS was 18.4 months (range 0.13–43.5, Figure 1) and the median OS 
was 28.1 months (range 0.13–54.4, Figure 2). There was no significant difference in PFS for 
patients in first relapse or second and more relapse. 
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Legend: Kaplan-Meier curve of progression free survival in patients with relapsed multiple myeloma.
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Combination therapy with bortezomib, cyclophosphamide and dexamethasone is effective 
for MM patients. The increased response rate of combination treatment might be the result 
of triggering different effector pathways. Bortezomib inhibits proteasome activity, leading 
to cell cycle arrest and apoptosis, while, low dose of continuous cyclophosphamide affects 
cell growth and neo-angiogenesis, and steroid-like dexamethasone have been used for a 
long time in myeloma treatment to inhibit cell growth and induce apoptosis10. Combining 
novel agents (such as bortezomib) with conventional chemotherapy (dexamethasone 
and cyclophosphamide) results in a deeper response with longer PFS3. In our study we 
showed a median PFS of 18.4 months after a median follow up of 29 months. Main toxicity 
included myelosuppression, which was predominantly observed during the first 3 cycles of 
chemotherapy, and PNP grade 3-4. These effects were observed in 15% of the patients. These 
results are comparable to the side-effect profile in the APEX study, in which grade 3-4 PNP 
was demonstrated in 8% of the patients6. The incidence of PNP will likely decrease when all 
the patients are treated subcutaneously11. 
Three other studies have analyzed the combination of bortezomib, dexamethasone and 
low-dose cyclophosphamide without maintenance therapy. The first study included 50 
patients which were treated with 11 cycles of bortezomib, dexamethasone and low-dose 
cyclophosphamide. The overall response rate was 82%, with a CR rate of 16% and the PFS was 
12 months; 10% of the patients experienced grade 3-4 toxicity12. In a second study, 37 patients 
were treated in phase I-II study with 8 cycles of bortezomib, dexamethasone and one weekly 
dose of cyclophosphamide (300 mg/m2). Overall response rate was 85% with a CR rate of 54% 
and a median PFS of 15 months. Grade 3-4 toxicity was observed in 30% of the patients13. In 
a third study, 18 frail elderly patients were included and treated with 8 cycles of bortezomib, 
dexamethasone and low-dose cyclophosphamide. The overall response rate was 83% with a 
PFS of 9 months14. In the present study, a comparable toxicity profile was observed but with 
more favorable PFS. It is unclear whether this relates to one year of maintenance therapy, 
since variability in co-morbidity, chromosomal aberrations and the type of pre-treatment 
might have significant impact. Supporting a positive effect of the maintenance therapy are the 
results of various upfront studies with bortezomib and lenalidomide maintenance therapy. 
Lenalidomide maintenance was associated with an improvement in PFS compared to placebo 
of approximately 40 vs. 21 months15,16. The data on OS are still too immature. Bortezomib 
maintenance has been given for a period of 2 years after ASCT. An upgrade in response after 
ASCT was seen in 23% of the patients receiving bortezomib maintenance. OS was improved 
with bortezomib maintenance compared to thalidomide maintenance4. Our result showed a 
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Our study demonstrates that combination therapy with bortezomib, continuous low-dose 
cyclophosphamide and dexamethasone, followed by one-year maintenance therapy, is an 
effective and manageable regimen for patients with relapsing MM. 
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Introduction: Previous studies have reported 5%-10% incidence of venous thromboembolism 
(VTE) in multiple myeloma (MM). Despite the recognized need for thromboprophylaxis, 
this rate may be higher in clinical practice. To determine the real-life risk of VTE in newly-
diagnosed MM patients treated with different regimes, we conducted a retrospective cohort 
study.
Methods: Two databases were used that prospectively registered consecutive patients with 
newly diagnosed MM. Data on thromboprophylaxis and VTE were retrospectively collected. 
Results: Between 2006 and 2013, 474 patients were registered; 58% were male, median age 
was 66 years (range 31-92). Thromboprophylaxis was prescribed to 64% of patients treated 
with immunomodulatory drugs (IMiD)-based regimens and to 31% in the non-IMiD-based 
regimens. VTE was diagnosed in 15% of patients at a median of 90 days (range 0-2026, 
interquartile range 66 –162) after diagnosis. VTE risk did not differ significantly according 
to first line treatment (IMiD 16%, non-IMiD 12%) or mode of thromboprophylaxis (aspirin 
20%, low molecular weight heparin (LMWH) 21%, no prophylaxis 12%) but was higher (24%) 
in patients treated with an autologous stem cell transplantation (ASCT)-based induction 
regimen. 
Conclusion: VTE risk in real-life MM treatment is unacceptably high at 15%, with similar rates 
in in all first line treatment regimens (both IMiD and non IMiD-based) and for both aspirin 
and LMWH. This is probably due to physicians tailoring prophylaxis to VTE risk. These findings 
suggest that the threshold for more effective thromboprophylaxis should be lowered, 
especially in patients eligible for ASCT. 












































Multiple myeloma (MM) is frequently complicated by venous thromboembolism (VTE). In 
recent years, the introduction of new treatment regimens has significantly increased the 
overall survival (OS)1,2. However, with new drugs and more intensive treatment schedules 
the risk of VTE have further increased. The cause of the increased incidence is not fully 
understood but seems to be linked to disease related-factors like the release of inflammatory 
cytokines, and treatment-related factors. Lenalidomide and thalidomide, belonging to the 
group of immunomodulatory drugs (IMiDs), are both known for a high incidence of VTE. 
Furthermore, patient-related factors, including genetic predisposition and immobility, may 
play a role3.
Published VTE rates in studies differ per regimen: for thalidomide-adriamycin-dexamethasone 
(TAD) the VTE incidence varies between 10% and 33%4, while for lenalidomide low-dose 
dexamethasone (Rd) the VTE incidence is 7%-12%4,5. For non-IMiD-based regimens, the 
incidence of VTE varies: for vincristine-adriamycin-dexamethasone (VAD) a VTE incidence of 
5% has been reported6, and for bortezomib-adriamycin-dexamethasone (PAD) an incidence 
of 6%6.
In 2008, the International Myeloma working group (IMWG) published guidelines for 
thromboprophylaxis for IMiD-based regimens, based on individual risk factors, myeloma-
related risk factors and treatment-related risk factors. The guidelines recommended aspirin 
for patients at low risk for VTE and low molecular weight heparin (LMWH) or full dose 
warfarin for patients at high risk4. Thromboprophylaxis was not recommended for patients 
being treated with proteasome inhibitors, like bortezomib. In 2015, the European Myeloma 
Network provided a guideline for the management of thromboprophylaxis. According to 
this guideline, aspirin should be given to patients who are being treated with an IMiD and 
are at low risk for VTE, and LMWH or warfarin should be given to patients at high risk for 
4-6 months7. High-risk patients were defined as those with 2 or more risk factors, including 
hyperviscosity, personal or family history of VTE, obesity, specific co-morbidities, chronic 
inflammatory disease, immobility, thrombophilia, recent surgery, and co-medications 
including oestrogen, adriamycin, and high-dose steroids (≥480 mg of dexamethasone/month). 
No thromboprophylaxis was recommended for patients being treated with proteasome 
inhibitors like bortezomib7. 
Despite these guidelines VTE still seems to occur frequently in clinical practice. A diagnosis of 
VTE has major impact given its morbidity and mortality, the need for full-dose anticoagulation 
with associated risk of bleeding, and delays in anti-myeloma treatment. We therefore decided 










































induction regimens. Our study was based on two existing databases covering four community 
hospitals and one tertiary academic haematology clinic, which is the referral centre for 
autologous stem cell transplantation (ASCT).
Materials and Methods
Patients
Patient data was extracted from two large prospective databases. One covered all four 
hospitals in the province Friesland, the Netherlands and the second the University Medical 
Centre Groningen (UMCG), the tertiary reference centre for the northern part of the 
Netherlands. In these databases, all consecutive patients were included at the time they first 
visited a haematologist for MM in one of the hospitals or when a bone marrow biopsy was 
performed for the diagnosis of MM. Patients diagnosed with MM in one of the four hospitals 
in the province, and who were eligible for ASCT, were referred to the UMCG. They were 
included in the dataset of the tertiary reference centre and not in the dataset for the four 
community hospitals. 
Methods
Eligible for inclusion were patients with newly diagnosed MM based on the IMWG criteria 
(Rajkumar et al., 2014). The databases contained information on demographics and first-
line treatment regimens, including watchful waiting policy for asymptomatic MM. In 
general, treatment was started when patients were symptomatic based on the CRAB criteria 
(hypercalcemia, renal-insufficiency, anaemia and bone lesions)8. 
Data on thromboprophylaxis and VTE diagnoses were collected from charts of patients 
included in the two databases. A VTE diagnosis was accepted when it was documented with 
ultrasound (DVT), CT angiography (PE) or other appropriate diagnostic modalities for VTE at 
unusual sites. The date of diagnosis was set as the date of these examinations. Furthermore, 
data on treatment regimens were confirmed, data on International staging system (ISS-
score) (only in the tertiary dataset) and co-morbidity (including diabetes, obesity and chronic 
kidney disease) were collected from the charts. Dutch law does not require ethical review for 
retrospective cohort studies based on chart review.
Statistical analysis
We described the baseline characteristics stratified by centre. The association between 
centre, sex, ASCT, age, treatment period, type of treatment and thromboprophylaxis with 
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Follow-up ended at last hospital visit, death or end of 2013 (for UMCG cohort)/end of 2014 
(for community hospitals cohort), whichever came first. 
Results
Patient characteristics
Between 2006 and 2013, data on 474 patients diagnosed with MM was entered in the 
dataset. We included all these patients in our study. Median follow up was 753 days (range 
4-2983). Patient characteristics are shown in Table 1. In total, 230 patients were treated 
in the community hospitals and 244 in the tertiary academic haematology clinic, including 
49 who were referred from the community centres to the tertiary academic haematology 
clinic for ASCT. Seven patients received their ASCT in another tertiary hospital, but induction 
chemotherapy and follow-up took place in the community hospital. They were included in 
the community hospitals cohort. In total, 58% were male, and the median age was 66 years 
(range 31-92). ISS score was I in 24%, II in 30%, III in 25% and not documented in 22%. Co-
morbidities included diabetes in 10%, obesity (Body mass index >30) in 9%, chronic kidney 
disease in 4%. Patients in the community hospital cohort were older, but rates of comorbidity 

















































(n= 230) n (%)
Age, mean (min,max) 66 (31-92) 60 (31-87) 73 (45-92)
Sex
Male 277 (58) 139 (57) 136 (59)
ISS score
I na 59 (24) na
II na 73 (30) na
III na 60 (25) na
unknown na 52 (21) na
Comorbity at baseline
Documented BMI >30 47 (10) 29 (12) 18 (8)
Diabetes 43 (9) 19 (8) 25 (11)
renal insufficiency 19 (4) 11 (5) 9 (4)
Treatment
ASCT 178 (38) 167 (68) 7 (3)
induction regimen
IMiD based 90 (51) 88 (53) 0
Bortezomib based 34 (19) 29 (17) 4 (63)
Vincristine based 43 (24) 41 (25) 2 (25)
Other 11 (6) 9 (5) 1 (12)
No ASCT 296 (62) 77 (32) 223 (97)
Wait and see 64 (22) 8 (10) 56 (25)
IMiD based 159 (54) 47 (60) 109 (49)
Bortezomib based 37 (12) 11(15) 27(12)
Other 36 (12) 11 (15) 31(14)
Na: not available, ASCT: autologous stem cell transplantation, VTE: venous thromboembolism, IMiD: 
immunomodulatory drugs, ISS: International staging system; BMI: body mass index.
Treatment 
Table 1 shows initial treatment regimens in the two cohorts. Thirty-eight percent of patients 
underwent ASCT. Most patients were treated with an induction chemotherapy combination of 
a novel agent and high-dose dexamethasone and adriamycin, mainly TAD or VAD. Patients not 
eligible for ASCT were treated with an IMiD-based regimen (mainly melphalan, thalidomide 
and prednisone), PI-based, or other, including watchful waiting. 
Thromboprophylaxis
Thromboprophylaxis was prescribed to 64% of the patients in the IMiD-based treatment 
group and to 31% in the non IMiD-based group, as shown in Table 2. This included a number 
of patients who previously received antithrombotic therapy for a co-morbid condition, for 
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Table 2: Thromboprophylaxis and VTE risk according to treatment regimen 
Type of 
thromboprophylaxis





based (n=217) n (%)
VTE incidence 
n (%)
Aspirin 105 (41) 25 (24) 31 (14) 2 (7)
LMWH 29 (11) 5 (17) 10(5) 3 (30)
VKA 26(10) 1 (4) 21(10) 1 (5)
Other 5 (2) 1 (20) 4 (2) 1 (25)
None 81 (32) 9 (11) 137 (63) 18 (13)
Unknown 11 (4) 1 (9) 14 (6) 2 (14)
Total thrombophrofylaxis 165 (64) 66 (31)
Total VTE incidence 42 (16) 27 (12)
VTE: venous thromboembolism, IMiD: immunomodulatory drugs, VKA: vitamin K antagonists.
VTE risk
VTE was diagnosed in 15% of the total population, a median of 90 days (range 0-2026, 
interquartile range (IQR) 66 –162) after date of diagnosis. VTE occurred in 24% of In patients 
treated with ASCT-based induction regimen, after a median of 89 days (range 0-2026, IQR 66 
– 129), so mostly at the end of induction treatment and before stem cell mobilization (Table 3 
and Figure 1). For patients treated without ASCT-based induction regimen, the VTE incidence 
was 9%, with a median time to VTE of 90 days (range 0-974, IQR 61 – 190). In the group 
receiving IMiD-based treatment, the total VTE burden was 16%; the proportion of patients 
with VTE was 24% for aspirin, 17% for LMWH and 11% for no tromboprophylaxis. In the non-
IMiD-based treatment group, the total VTE burden was 12%; the proportion of patients with 
VTE was 7% for aspirin, 30% for LMWH and 13% for no tromboprophylaxis (Table 2). Patients 
treated with VKA had the lowest VTE incidence: 4% in the IMiD-based treatment group and 
5% in the non-IMiD-based groups.
Table 3: VTE risk based on treatment regimen IMiD-based or non-IMiD-based and ASCT or no 
ASCT and compared with treatment before and after 2008
Initial 
therapy 
Proportion with VTE 
(n=474) (patients with 
VTE/total patiets) (% with 
VTE)
Proportion VTE treatment 
before 2008 (n=111) 
(patients with VTE/total 
patiets) (% with VTE)
Proportion VTE treatment 
after 2008 (n=363) 
(patients with VTE/total 
patiets) (% with VTE)
ASCT   42/178 (24) 13/53 (25) 29/125 (23)
IMiD 27/97 (28) 0/3 (0) 27/94 (29)
non-IMiD 15/81 (19) 13/50 (26) 2/31(7)
No ASCT 27/296 (9) 8/58 (14) 19/238 (8)
IMiD 15/160 (9) 4/30 (14) 11/130 (9)
non-IMiD 12/136 (9) 4/28 (13) 8/108 (7)
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Treatment before and after publication of guidelines 2008
In 2008, the first guidelines were published recommending VTE prophylaxis for patients 
treated with IMiD, as described in the introduction4,7. In our cohort the total proportion 
of patients with VTE before 2008 was 19%, compared to 13% after 2008 (p=0.501). Table 
3 shows the VTE proportions, before and after 2008, stratified for treatment regimens 
and ASCT status. Although more thromboprophylaxis was prescribed after 2008, no clear 
differences are apparent (Table 4). In the IMiD-based group, ‘no prophylaxis’ decreased 
from 42% before 2008 to 30% after this date. In the non-IMiD-based group, no difference 
was seen (no prophylaxis in 67% vs 61%). According to the guidelines, patients treated with 
TAD should be considered high risk for VTE and should have received LMWH4. After 2008, 
however, only (21/94 (22%) patients treated with TAD before ASCT received LMWH or VKA; 
64% were prescribed aspirin and 5% had no thromboprophylaxis at all. After publication of 
the guidelines in 2008, we observed no increase in the use of LMWH (11% in the IMiD-based 
group, compared to 12% before 2008 (Table 4).















Aspirin 9 (27) 96 (43) 6 (7) 25 (18)
LMWH 4 (12) 25 (11) 4(5) 6 (4)
VKA 5(15) 21 (9) 5(6) 16 (12)
Other 0 5 (2) 0 4 (3)
None 14 (43) 67 (30) 52 (67) 85 (61)
Unknown 1 (3) 10 (5) 11 (14) 3 (2)
IMiD: immunomodulatory drugs, VKA: vitamin K antagonists, LMWH: low molecular weight heparin.
Multivariate analysis (Table 5) showed a significantly increased risk of VTE in patients treated 
with ASCT- based induction regimen (p=0.031), but no effect of centre, sex, older age or 










































Table 5: Multivariate analysis for VTE burden
 VTE burden  
 HR (95% CI) p
Center 1.125 (0.518 – 1,442) 0.767
Male 0.774 (0.470 - 1.274) 0.313
ASCT 2.454 (1.085 - 5.548) 0.031
Age > 65 0.983 (0.486 -1.991) 0.963
Treatment before 2008 0.731 (0.397 -1.344) 0.313
Treatment IMiD-based 1.182 (0.678 -2.061) 0.555
Thromboprophylaxis regimen
None 0.297
Aspirin 1.379 (0.762 -2.498) 0.288
LMWH 1.259 (0.535 -2.961) 0.598
VKA 0.366 (0.086 -1.551) 0.172
ASCT: autologous stem cell transplantation, VTE: venous thromboembolism, IMiD: immunomodulatory 
drugs, VKA: vitamin K antagonists, LMWH: low molecular weight heparin.
Discussion
In this retrospective cohort study, we found a VTE risk of 15% in newly diagnosed MM patients 
treated with different induction regimens. In this real life setting where clinicians could 
choose thromboprophylaxis, we found that IMiD-based therapy and thromboprophylaxis 
regimen were not associated with VTE risk. However, in patients who underwent induction 
chemotherapy followed by an ASCT, we observed a VTE risk of 24%. Indeed, multivariate 
analysis showed only planned treatment with an ASCT-based induction regimen as a significant 
prognostic factor for developing VTE. VTE occurred median at 89 days (range 0-2026, IQR 66 
– 129) after diagnosis, probably during induction chemotherapy. 
Similar results have been reported in other population-based studies. The Melisse study, a 
French multicentre prospective observational study, included 524 MM patients. This cohort 
differed from ours in that the majority of patients had relapsed disease, all were treated with 
an IMiD (lenalidomide in 64% and thalidomide in 36%) and most were ineligible for ASCT. As in 
our study, thromboprophylaxis was prescribed at the treating physician’s discretion. Overall, 
6% developed VTE9, similar to our results. However, our study included newly diagnosed 
patients eligible for ASCT and treated accordingly, who appear to have a significantly higher 
risk of VTE.
The Melisse study also showed that patients at high risk (based on the risk assessment before 
starting treatment) for VTE received more intensive VTE prophylaxis with LMWH and VKA9. 
This is consistent with our findings: clinicians were able to assess classical risk factors for VTE 
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Possible explanations for the higher VTE risk in real-life patients are differences in patient 
characteristics between trials and observational cohorts, or the use of suboptimal 
thromboprophylaxis in real life. This explanation is supported by our finding that 64% of 
patients received aspirin although LMWH was indicated based on the TAD regimen. An 
explanation for this could be the wish to avoid injections. Patient comfort could be increased 
if the direct oral anticoagulants (DOAC) would be registered/available for this indication.
However, non-adherence to the guidelines is not the whole issue. In case of treatment 
with VAD or PAD no thromboprophylaxis should be given based on the guidelines, but 
VTE still occurred in 19% of these patients. The same is true for treatment with high-dose 
dexamethasone and adriamycin despite treatment with a non-IMiD-based regimen. This 
confirms previous finding that MM, especially if newly diagnosed and with high tumour load, 
is separately associated with a high VTE risk3.
In our cohort only patients on full anticoagulation with VKA had a low VTE risk. This might 
indicate that the intensity of anticoagulation achieved with a prophylactic dose of LMWH is 
insufficient. Nadroparin 2850 U is used routinely, but higher doses are considered prophylactic 
in other high-risk situations (e.g. acute lymphoblastic leukaemia10 and obstetrics11. No studies 
comparing different doses of LMWH have been performed in MM.
Our retrospective cohort study has some limitations. The risk assessment for VTE was not 
performed (or documented) systematically for all patients. It was not possible to reliably 
differentiate between patients with a high risk and low risk for VTE since (especially absent) 
risk factors were not always documented. We could therefore not assess adherence to the 
guidelines on an individual basis. Strengths of the study are the prospective registration of 
patient demography and treatment, and the inclusion of a diverse population of patients, 
covering all newly diagnosed MM.
In conclusion, based on the results of our study, we recommend stricter adherence to the 
guidelines. In addition, all patients eligible for an induction regimen followed by ASCT should 
be considered high risk, including those not treated with an IMID. We recommend that 
physicians continue to be aware of VTE risk in MM patients and tailor thrombophophylaxis 
not only to treatment regimens, but also to patient characteristics. Our findings indicate that 
there should be a lower threshold for starting thromboprophylaxis and for LMWH instead 
of aspirin, in accordance with the guidelines. Future studies should address the dose of 
LMWH, comparing standard prophylaxis with an intermediate dose. Another possibility, with 
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Plasmacytoma is characterized by a local accumulation of monoclonal plasma cells without 
criteria for multiple myeloma (MM). The current treatment regimen is local radiotherapy. 
However, more than 50% of the patients develop MM within 2 years after treatment.
A population-based registry was consulted for the diagnosis of solitary plasmacytoma 
between 1988 and 2011. Progression to MM and prognostic features for progression to MM 
were scored, including hypoxia inducible factors (HIF), vascular endothelial growth factor 
(VEGF), and micro-vessel density (MVD) expression in biopsy material.  
76 patients were included, 34% having extramedullary plasmacytoma (EMP) while 66% had a 
solitary plasmacytoma of the bone (SBP). Median follow up was 89 months, (7-293 months). 
In SBP patients 70% developed MM with a median time to progression of 19 months (5-293). 
Three patients (12%) with EMP developed MM. High expression of VEGF and HIF-2α was 
demonstrated in conjunction with an increased MVD in 66% of the patients. No association 
could be shown between angiogenesis parameters and progression to MM.
 In conclusion this population based study demonstrates that SBP patients have a higher risk 
of developing MM following local radiotherapy, indicating that this group might benefit from 
added systemic chemotherapy.
Key Words: Solitary plasmacytoma of the bone, extramedullary plasmacytoma, multiple 












































A solitary plasmacytoma (SP) is defined as a solitary lesion of clonal malignant plasma cells. 
About 80% of the SP are localized in the bone marrow compartment (SBP) while in the 
remaining cases it is localized extramedullary and called extramedullary plasmacytoma (EMP). 
A SP is a rare condition with an onset at a median age of 55 years, which is approximately 
ten years younger than multiple myeloma (MM) patients1,2. By definition a plasmacytoma 
has no criteria of Multiple Myeloma (MM) except for a small amount of M-protein, which is 
described in 25-75% of the patients1-3. 
The current treatment of a plasmacytoma with curative intent is local radiotherapy. However, 
more than 50% of the patients develop MM within 2 years after treatment1,2. In view of this 
unfavorable prognosis, several studies tried to identify predictive markers for progression 
including age, lesion size > 5 cm and persistent M-protein one year after treatment4,5. 
However, none of the features are consistent between the different studies except that SBP 
has a higher rate of progression to MM than EMP. Approximately two-third of the patients 
with SBP develop MM while only 10-20% of the EMP progress to MM1,2. In addition, tumor 
specific markers have been studied such as micro-vessel density (MVD), which is a reflection 
of increased (neo)-angiogenesis. In a study of SBP patients an increase in MVD coincides with 
an increased risk to progress to MM6. 
In the present population-based study we evaluated the clinical parameters of SP patients and 
correlated these findings with myeloma progression. In addition MVD and (neo)angiogenesis 
related factors were studied such as vascular endothelial growth factor (VEGF) and hypoxia 
inducible factors (HIF) 1α and 2α in biopsies of plasmacytoma patients. We correlated these 
findings to progression to MM to determine whether they can be used as prognostic features. 
Materials and Methods
Patients
In this retrospective multicentre study, all patients with a SP diagnosed between 1988 and 
2011 in the north part of the Netherlands were included. Inclusion criteria were biopsy-
proven plasmacytoma, follow up of at least 6 months, bone marrow demonstrating less than 
10% plasma cells and skeletal survey showing no other lytic lesions than the solitary lesion of 
the plasmacytoma.
Data were collected at time of diagnosis and included the number of plasma cells in bone 










































Results from different imaging techniques like MRI, FDG-PET and CT were included when 
performed. Furthermore, the applied treatment regimens, and the M-protein level one year 
after treatment were collected. Progression to MM was defined as the moment patient 
started systemic treatment for MM.
Approval for the study was obtained from the local medical ethical committee.
Immunohistochemistry for MVD, VEGF-A, HIF 1α and 2α 
Biopsies were collected from different pathology laboratory. The expression of angiogenesis 
and hypoxia related features was examined by immunohistochemical staining. After 
fixation in 10% neutral phosphate buffered formalin (3.6% formaldehyde) for at least 12h, 
decalcification in a solution containing 10% (v/v) acetic acid and 10% formalin (v/v; 3.6% 
formaldehyde) for 1 or 2 days, and paraffin embedding, the plasmacytoma biopsy was cut in 
sections of 4 µm and stained as follow. Slides were deparrafinized and rehydrated in graded 
alcohol solutions. Endogenous peroxidase activity was blocked with hydrogen peroxide. 
Heat-induced antigen retrieval was performed, in all stainings except for the VEGF (in which 
antigen retrieval was done with protease 0.1%). Slides were incubated with the primary 
antibody for HIF-1α (mouse monoclonal clone 54/HIF-1α BD Biosciences, Franklin Lakes, 
New Jersey USA; diluted 1:70) HIF-2α (mouse monoclonal ab8365, Abcam, Cambridge, UK; 
diluted 1:200) and VEGF-A (rabbit polyclonal sc-152, Santa Cruz, Dallas, Texas, USA; diluted 
1:50). Blood vessels were visualized with a CD34 antibody (mouse monoclonal QBEnd 10, 
Dako, Copenhagen, Denmark). The slides were washed with PBS and subsequently incubated 
with a rabbit anti mouse or goat anti rabbit horse-radish peroxidase conjugated as secondary 
or tertiary antibody. For the VEGF staining streptavidine peroxidase was used as a tertiary 
antibody. The chromogenic reaction was performed with diaminobenzidine for 12 min and 
after that sections were counterstained with haematoxylin before dehydrating and mouting.
The intensity of staining was analyzed semi-quantitatively. The percentage of positive plasma 
cells was counted according the following scoring system: no visibility, 10-30% positive, 30-
50% positive, 50-80% positive and more than 80% positive plasma cells7. The vessel count was 
measured using light microscopy in areas of the slide containing highest numbers of blood 
vessels per selected area (hotspot). After the hotspots were identified, the total number of 
vessels per selected image was counted at 400 magnifications. At least five hotspots were 
counted for each section and the true vessel number was expressed as the mean of five 
counts8. The grade of MVD was established: low (MVD lower than 20) and high (MVD 20 or 
higher)6. 
Statistical analysis
Progression free survival (PFS) was estimated as time from diagnosis of the plasmacytoma 
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were compared using the log rank test. In addition, univariate Cox regression analysis was 
used to estimate associated risk estimates i.e. hazard ratio’s (HR) with 95% confidence 
intervals (95%CI). A P value < 0.05 was used to define statistical significance.
Results
Patient characteristics
Between 1988 and 2011, 76 patients diagnosed with a SP were included in this study. Patient 
characteristics are shown in Table 1. Median follow up was 89 months (range 7-287 months). 
Median age was 61 years (range 26-87) and 60% were male. Most of the patients (66%) 
had an SBP. The plasmacytoma was located in the axial skeletal in 78% of the SBP patients. 
In the EMP patients the plasmacytoma was most frequently located in the oropharynx or 
nasopharynx (65%). Most of the patients had an IgG-M-protein (46%), 4% had free light chain 
disease only and 43% had no M-protein. Median M-protein was 0 gr/l (range 0-22.8 gr/l). 
In view of the time frame of the study, a MRI was only performed in 42% of the cases, but 
mainly for diagnostic purpose of the affected area. FDG-PET scan was performed in 11% 
of the patients (n=8). Size of the plasmacytoma was only documented in 20 cases (25%). 




























































































































Treatment consisted of local radiotherapy in 91% of the patients, 7% of the patients received 
systemic chemotherapy and 11% surgical removal in combination with local radiotherapy. 
One patient was not treated. The radiotherapy dose was >40 Gy in 89% of the patients. A 
limited number of patients (n=8) had a lower dose (20-39 Gy) due to the combined treatment 
of radiotherapy and chemotherapy. 
Progression to MM
Local relapses of the plasmacytoma were not observed. Of patients with a SBP, 70% 
progressed to MM after median time to progression of 19 months (range 5-131), Fig 1). Of 
patients with EMP 12% (n=3) progressed to MM after 6, 33 and 71 months. The 5 year PFS 
was significantly different between SBP and EMP (38% vs. 93%, p=0.0001). However, the 
overall survival (OS) between SBP and EMP was not significantly different (p= 0.294) with an 
overall survival of 70% vs. 81% at 5 year and 64% vs. 77% at 10 years, mainly because 4 EMP 
patients died within 5 years of diagnosis due to disorders unrelated to MM.
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MVD, HIF, and VEGF expression by clonal plasma cells. 
To define whether tumor related predictors can be defined for the difference in PFS between 
SBP and EMP, immunohistochemical staining’s on plasmacytoma biopsies were performed 
on SBP (n=13) and EMP (n=9) (Fig 2). 




















 Legend: Immunohistochemical staining on biopsies from a solitary bone plasmacytoma (SBP) and extramedullary plasmacytoma (EMP) A: HIF-1α, B: HIF-2α C:VEGF and D:MVD. HIF; hypoxia inducible 
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Six patients progressed to MM (5 SBP patients and 1 EMP patient). All biopsies (n=22) 
demonstrated increased MVD as defined by CD34 positive staining in comparison to normal 
bone marrow (3.5 ± 2.9 (mean ± SD) vessel number power field9. The MVD between SBP and 
EMP was not significantly different (p=0.5). Since an increase in MVD might be a reflection 
of locally produced VEGF triggered by hypoxia, the expression of HIF-1α and HIF-2α and 
VEGF by the plasma cells were studied. A clear distinction was observed for HIF-1α and HIF-
2α. HIF-1α was demonstrated in plasma cells in a minority of the cases (36%) although the 
surrounding endothelial cells demonstrated a distinct positive staining. Staining with HIF-2α 
and VEGF-A were positive in more than 80% of the plasma cells in all of the studied samples 
and no difference was observed between SBP and EMP as depicted in Fig 3. 


























 Legend: Precentage of patients with a positive staining in at least of 80% of the plasma cells. SBP: 
solitary plasmacytoma of the bone; EMP: extramedulary plasmacytoma: HIF: hypoxia inducible factor; 
VEGF: vasculair endothelial growth factor; MVD: micro vessel density (depicted in absolute numbers).
Finally all defined in vivo and in vitro prognostic parameters were included in a univariate 
Cox regression analysis. No association with progression to MM was observed except for the 
localization of the plasmacytoma (SBP vs EMP; HR = 8.9, 95% CI = 2.7-29.1, p=<0.001), as 
depicted in table 2. For the parameters persistent M-protein one year after treatment and 










































Table 2: Cox regression analysis for progression to MM
HR 95% CI p
SBP vs EMP <0.001
SBP 8.9 2.7 to 29.1
EMP 1
Age
60 years of older 1.5 0.78 to 2.8 0.23
up to 60 years 1
M-protein at diagnosis 0.95
0 1
0 to 6.9 gr/l 1.1 0.49 to 2.6
> 6.9 gr/l 0.95 0.42 to 2.2
% plasma cells at diagnosis 0.62
up to 2% 1
3% 1.2 0.53 to 2.6
> 3% 1.5 0.68 to 3.1
Bence Jones proteinuria 0.71
negative 1
positive 0.80 0.24 to 2.6
HIF-1α 0.53
negative 1






low 2.6 0.51 to 13.9
high 1
Cox regression analysis for progression to MM. SBP: solitary plasmacytoma of the bone; HIF: hypoxia 
inducible factor; VEGF: vasculair endothelial growth factor; MVD: micro vessel density. 1 All patients 
had a value >80%, hazard ratio not estimable.
Discussion
In this large population based cohort we showed that despite optimally local control with 
radiotherapy, patients with a SBP are at high risk for progression to MM with a median time 
to progression of 19 months. No association with progression to MM was observed for other 
prognostic parameters. However, no consistent results with regard to prognostic parameters 
have been obtained between the different studies except for the difference between SBP vs. 
EMP4,5. 
In addition tumor related factors like MVD, VEGF and HIF-2α expression was studied and 
demonstrated increased expression but without significant difference between SBP and EMP. 
Also no association with progression to MM was demonstrated in contrast to a large cohort 








































Solitary plasmacytoma and progression to MM
105
7
The difference might be due to the smaller number of patients studied. In addition, in this 
cohort we had a relative high number of EMP (34%) patients in which 78% had a high score 
on the MVD, but with a low-relapse rate suggesting that both factors are not interconnected. 
Nowadays more sophisticated techniques can be used for the diagnosis of SP. As advised 
by the international myeloma working group (IMWG) staging of SBP includes a magnetic 
resonance imaging (MRI) of the spine and pelvis11. This is based on a small series by Lieboss 
et al12, in which 15 SBP patients were studied. In our study MRI was performed in 42% of the 
patients but mainly for diagnostic purpose without performing a MRI of the spine and pelvis. 
Only limited patient numbers are reported regarding the relevance of fluoro-D-glucose 
positron emission tomography (FDG-PET) scanning at diagnosis for SBP13,14. In the present 
study 8 patients had a FDG-PET scan at diagnosis, 3 with an EMP and 5 with a SBP. Four of the 
8 patients progressed to MM. Remarkably all 3 patients with an EMP progressing to a MM 
had a negative FDG-PET but still progressed to MM.
Recent studies have demonstrated that more careful study of the bone marrow of SBP 
patients results in identification of a clonally related plasma cell population in 68% of 
the patients. The presence of this occult bone marrow disease (OMD) is of prognostic 
significance and is highly predictive for progression to MM, with a TTP between 18-26 
months15,16. The strong predictive value of OMD and the short PFS supports the potential use 
of systemic treatment in addition to local radiotherapy in this high risk group of SBP. Avilés 
et al. previously compared radiotherapy with and without melphalan/prednisone therapy 
for 36 months in 58 patients. After a median follow up of 8.9 years 21% of the patients in 
the melphalan/prednisone group progressed versus 53% in the radiotherapy group17. In that 
study the high-risk SBP patients were not identified and treatment was without the use of 
the more effective immunomodulatory derivatives (IMIDs) and proteasoom inhibitors. For 
the future early treatment may prevent or delay symptomatic disease in this high risk group 
as has been shown in the group of high risk smoldering MM of which 50% progress to MM 
within 2 years. Treatment with lenalidomide and dexamethasone compared to no treatment 
had a superior PFS and OS. Moreover, clinical significant symptoms were reduced by the 
treatment18. A study using a combination of an IMID and a proteasoom inhibitor in addition 
to local radiotherapy in high-risk SBP is now being developed.
In conclusion, based on the population based cohort in our retrospective study, patients 
with SBP who are treated with local curative radiotherapy appear to have a high risk of 
developing MM. Adding systemic treatment with novel agents like proteasome inhibitors or 
immunomodulating drugs might improve the outcome of this patient group 
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Scleromyxedema is a rare disease which mimics systemic sclerosis. Subtle differences are 
a waxy non-pruritic eruption over the thickened skin, and the more proximal onset of skin 
thickening. Systemic manifestations include gastrointestinal, lung or heart involvement. 
In scleromyxedema the fibroblast is affected by an unrecognized mechanism, resulting in 
excessive mucin deposition1. Most intriguing is the finding of a paraprotein type IgG lambda 
(IgG-λ) in 80% of cases which is the basis that patients are frequently treated with regimens 
according to myeloma patients. 
A 45-year-old woman was referred to our hospital for progressive thickening and tightening 
of the skin. Her medical history revealed a transient ischemic attack and hypertension three 
years before presentation. During the last two years she noted a progressive skin thickening. 
Due to the thickening of the skin she could not make a tight fist. She recently noticed 
Raynaud’s phenomenon without other complains. A skin biopsy revealed the diagnosis 
scleromyxedema. In the same period a ductal carcinoma of the right breast was diagnosed 
(T1N0M0). Treatment consisted of lumpectomy and radiotherapy, but skin abnormalities 
progressed in the following six months. 
At presentation her general physical examination was unremarkable. Her musculoskeletal 
and skin examination revealed a thickened skin of the fingers, wrists, upper arms, shoulders, 
around the mouth and forehead, and the upper and lower legs which resulted in a modified 
Rodnan total skin score (mRTSS) of 34 out of 512. A skin-colored papular eruption was present 
at the wrists. She was not able to make a tight fist, and had a reduced oral aperture of 4 cm.
Laboratory investigations showed no abnormalities apart from an IgG-λ of 5.7 g/l. Free light 
chain lambda and kappa concentrations were within the reference ranges. ANA and ENA 
were negative, complement C3 1.1 g/l, complement C4 0.2 g/l, rheumatoid factor 10 kIU/l. 
Further investigations of internal organs showed reduced digital perfusion after cooling, a 
normal pattern at nailfold capillary microscopy, a disturbed esophagus scintigraphy indicating 
dysmotility and a slightly reduced lung diffusion capacity of 78% of predicted. Bone marrow 
biopsy and cytogenetic analysis, subcutaneous fat biopsy for amyloidosis, radiology of the 
skeleton and cardiac ultrasound did not show any abnormalities. 
In view of the clinical findings and the relation between scleromyxedema and IgG-λ paraprotein, 
we decided to treat the patient according a multiple myeloma protocol. This consisted for 
three months of the combination of thalidomide (100 mg daily) and dexamethasone (40 
mg days 1-4 and day 16-20 each month)3. There was a significant improvement of clinical 
symptoms. The mRTSS decreased from 34 to 2, and the paraprotein disappeared. Peripheral 
blood stem cell mobilization and collection was performed with cyclophosphamide, 
adriamycin and dexamethasone (CAD)3, followed by granulocyte-colony stimulating factor 
10 μg/kg (G-CSF) subcutaneously till stem cell harvest. Subsequently, the patient was treated 










































complications. Current follow-up till 31 months showed a mRTSS of 0 without paraprotein. 
Her Raynaud’s phenomenon disappeared and the ranges of motion of her oral aperture and 
the wrists returned to normal. ANA screening remains negative.
For scleomyxedema different treatment regimens have been applied, including corticosteroids, 
hydroxychloroquine, azathioprine, interferon, cyclophosphamide, oral melfalan, and 
intravenous immunoglobulin, with disappointing results. However, especially treatment with 
high-dose chemotherapy directed against the aberrant monoclonal plasma cell population 
showed positive results in line with results obtained in AL-amyloidosis and POEMS disease4.
In 2001 Donato et al were the first to describe the positive results of high dose melphalan in 
the setting of autologous stem cell transplantation (ASCT) in scleromyxedema. In 2006, the 
same group published a cohort of 7 patients treated with ASCT5. In this study no induction 
regimen was applied before ASCT. Also, most of the included patients had extensive disease, 
some requiring tube feeding due to gastrointestinal dysfunction. From 2001 till now ASCT has 
been described in 17 scleromyxedema patients including our patient as depicted in Table 1. 



















(n=4; 4, 8, 12 
months)











14, 37 and 45 
months)
III7 n=1 No Cyclo plus G-CSF BU plus
melphalan 
(140 mg/m2)
CR CR (>60 
months)




V9 n=1 No BEAM PR PR (>36 
months)
VI10 n=1 No G-CSF HDM NE, †
VII* n=1 dexamethasone/
thalidomide
CAD plus G-CSF HDM CR CR (31 months)
G-CSF: Granulocyte colony-stimulating factor; CR: complete remission; PR: partial remission; Cyclo: 
cyclophosfamide; HDM: High dose melphalan (200 mg/m2); BU: busulfan; ASCT: autologous stem 
cell transplantation; BEAM: BCNU, etoposide, ARA-C and melphalan; NE; not evaluable; CAD; 











































Complete remission (CR) defined as disappearance of all the clinical symptoms, skin 
abnormality and serum paraprotein was obtained in 58 % and partial remission (PR) defined 
as significant improvement but without normalization was obtained in 29 % of the patients. 
At a median follow up of more than 40 months (range 14 - >60 months) persistent CR was 
only demonstrated in 12% of patients. 
These data demonstrate the positive effects of intensive chemotherapy directed against the 
aberrant plasma cell population in scleromyxedema. However, a high number of patients 
relapsed which might be due to the fact that the transplantation was performed at a late 
stage of the disease. Further improvement might be obtained by applying a pre-induction 
regimen with thalidomide and dexamethasone upfront ASCT thereby reducing the total 
tumor mass before transplantation which might further improve the long-term outcome. 
Rheumatology key message
Treatment of scleromyxedema with a pre-induction of thalidomide and dexamethasone 
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Plasma cell dyscrasia and related diseases include a variety of disorders, all arising from 
monoclonal plasma cells in the bone marrow, but with variations in clinical presentation. 
Multiple Myeloma (MM) is the most frequently diagnosed plasma cell dyscrasia. Treatment 
is initiated when the CRAB criteria are met or when high-risk features are presented. Lytic 
bone lesions are an important source of morbidity in patients with MM. In recent years, bone 
lesions have been diagnosed more effectively with CT imaging and different nuclear tracers 
(radiopharmaceuticals). Treatment of MM has also improved substantially during the last 
decade. Much research has focused on optimization of diagnostic tests, treatment options 
and response monitoring.
Besides MM, several rare diseases are also linked to plasma cell dyscrasia which can be 
accompanied by severe clinical symptoms. Due to their rarity, they are frequently unrecognized 
and difficult to diagnose. Most frequently these diseases are treated with agents targeting 
the malignant plasma cells. 
The aim of this thesis is to evaluate several aspects of malignant plasma cell disorders based 
on new imaging techniques and treatment regimens.
Chapter 2 provides a review of the various nuclear tracers that can be used to visualize MM 
activity in patients. Nuclear imaging techniques can be used not only for diagnostic purposes 
but also for response monitoring. Nuclear tracers have been developed to detect bone 
lesions, including the bone marrow and the extramedullary compartment. The properties 
of nuclear imaging enable the identification of specific cellular properties of the malignant 
plasma cells. For example, [18F]-FDG-PET recognizes the glucose metabolism and can be 
used not only as diagnostic test but also for treatment monitoring. 
Chapter 3 describes the osseous involvement of MM defined with the use of whole body 
X-ray (WBX), [18F]-FDG-PET and somatostatin receptor scintigraphy (SRS). High expression 
of somatostatin receptors can be seen on malignant plasma cells. The use of WBX is limited 
by the fact that more than 30% of the trabecular bone must be lost before lesions can be 
visualized. The lesions also persist following chemotherapy, thereby limiting its usefulness 
during the treatment of relapsing disease. The purpose of the study presented in this chapter 
is to identify the most optimal technique for detecting skeleton lesions in patients with 
relapsing MM. The results indicate that SRS detects more lesions than WBX, but that [18F]-










































Chapter 4 reports on a study in which [18F]-FDG-PET and [18F]-Fluoroazomycin arabinoside 
([18F]-FAZA) were used to demonstrate whether positive lesions on the [18F]-FDG-PET 
scan have a low oxygen content reflected by an increased uptake of [18F]-FAZA. In addition 
immunohistochemical stainings on bone marrow biopsies were performed to determine 
whether [18F]-FDG-PET uptake coincides with angiogenesis-related tumor hypoxia. The 
results showed that [18F]-FDG-PET can detect focal lesions, but increased hypoxia cannot 
be shown by [18F]-FAZA scans. Immunohistochemical stainings showed that increased HIF-
2α expression in a high number of patients occurs in conjunction with an increase in MVD 
and elevated expression of VEGF, suggesting that the HIF signaling pathway was activated. 
Different expression patterns of HIF-1α and HIF-2α have been described, suggesting different 
roles for both factors. It has been proposed that HIF-1α increases directly in response to 
hypoxia, while HIF-2α is responsive during prolonged period of hypoxia. Furthermore, 
alternative pathways can be activated due to oncogene activation or mutations that trigger 
the expression of HIFs. 
In Chapter 5 a study in relapsing MM patients with combination therapy of bortezomib, 
dexamethasone and low-dose oral cyclophosphamide as induction regimen followed 
by one year of maintenance therapy consisting of bortezomib and cyclophosphamide is 
described. Maintenance therapy might be an effective and tolerable manner to improve 
PFS. The study demonstrates that treatment with bortezomib, dexamethasone and low-dose 
cyclophosphamide is an effective and manageable regimen. Adding one year of maintenance 
therapy was feasible, with limited side effects and an increased response rate.
Thrombose prophylaxis is generally given to MM patients who are treated with an IMID-
containing regimen, but the efficacy of this approach in real life setting is not well defined. 
Chapter 6 reports on a retrospective analysis that was performed in an unselected patient 
population to determine real-life incidence of VTE in newly diagnosed MM patients treated 
with different anti-myeloma regimes, with and without thromboprophylaxis. The data showed 
that VTE risk during real-life MM treatment is unacceptably high at 15%, with similar rates in 
all first line treatment regimens with and without thromboprophylaxis. 
The final part of this thesis highlights rare plasma cell dyscrasias. Chapter 7 describes a 
dataset of patients with plasmacytoma that was collected in a population-based registry 
in the northern region of the Netherlands. Progression to MM and prognostic features for 
progression to MM were scored, including analyzing angiogenesis parameters in the tumor. 
This population-based study demonstrates that solitary bone plasmacytoma patients are at 
high risk of developing MM following local radiotherapy. Except for localization, no other 
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Chapter 8 describes the clinical presentation and treatment options of patients with 
scleromyxedema. This disease mimics systemic sclerosis with a wide range of systemic 
manifestations. The most intriguing finding is the presence of an M-protein; this is why 
scleromyxedema patients are frequently treated with regimens that are also used for MM 
patients. In this chapter, a patient is described who was treated with thalidomide and 
dexamethasone, followed by ASCT. After 7 years, the patient is still in complete remission, 










































Discussion, future perspectives and conclusions
In recent years, the diagnostic approach to multiple myeloma (MM) has shifted, with CT-
imaging increasingly being used for the detection of lytic bone lesions. CT imaging has several 
advantages compared to whole body X-ray. It can be performed easily, more lesions are 
detected including extramedullary lesions  and its use is not dependent on kidney function, 
as no intravenous contrast is required. A disadvantage, however, is that this imaging modality 
cannot be used to monitor disease activity, with old lesions remaining visible for a long time 
on CT scans. 
Nuclear imaging is a unique whole-body imaging technique for visualizing and quantifying the 
molecular properties of disease activity. Nuclear imaging is particular helpful for distinguishing 
between old and new lytic bone lesions in relapsed MM. This thesis describes several tracers 
that can be useful for detecting bone lesions in relapsed MM. [18F]-FDG-PET is the most 
commonly used metabolic tracer; it detects more new bone lesions than WBX, can be used 
to monitor disease activity, and can be of particular value in MM patients with limited disease 
specific-markers, such as M-protein or free light chains. Despite the diagnostic advantage of 
[18F]-FDG-PET in MM patients, 20% to 25% of the patients have a negative [18F]-FDG-PET 
scan despite the presence of symptomatic MM. This is likely due to the low tumor burden 
or lack of ossal involvement, with lesions remaining below the detection threshold of [18F]-
FDG-PET. Large cohort studies have indicated that >3 focal lesions on the [18F]-FDG-PET is a 
poor prognostic marker, suggesting that a negative [18F]-FDG-PET scan may be a favorable 
prognostic marker. However, recent data have compared [18F]-FDG-PET and diffusion-
weighted magnetic resonance imaging with background signal suppression (DWIBS). In 11% 
of the cases, DWIBS was positive but [18F]-FDG-PET was negative. Extensive research showed 
that expression of the gene encoding for Hexokinase-2 was significantly lower in PET “false” 
negative cases. This gene encodes the first step of glycolysis and may explain the negative 
[18F]-FDG-PET findings1. Thus, caution should be observed when drawing conclusions based 
on a negative [18F]-FDG-PET scan. More sensitive or myeloma-specific tracers are required 
to provide better markers for myeloma activity.
Alternative tracers that can target other cell biological properties of the malignant plasma 
cells are currently available. Studies with 11C-Methione (11C-MET) has shown that this 
imaging technique can detect more bone lesions compared with [18F]-FDG-PET, particularly 
when a low number of aberrant plasma cells are present in the bone marrow. Based on these 
properties, 11C-MET seems a promising tracer for detecting active bone lesions in patients 
with a negative [18F]-FDG-PET scan. However, there are constraints on the widespread use of 
11C-MET due to its relatively short half-life of approximately 20 minutes, which necessitates 
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A more interesting approach is the use of more specific tracers targeting myeloma. Plasma 
cells have very high CD38 expression. Daratumumab, a monoclonal antibody against CD38, is 
now widely used in studies for treating MM. It would be interesting to see whether scanning 
with radiolabeled anti-CD38 can provide better and more myeloma-specific imaging than 
[18F]-FDG-PET, particularly in FDG-negative cases. A disadvantage may be that CD38 is still 
not fully myeloma-specific. For example, several white blood cells, including CD4+-, CD8+-, 
B- lymphocytes and natural killer cells, express CD38 at relatively low levels which may result 
in false positives. Another potential treatment option involves radio-immunotherapy using 
therapeutic radioactive labeled (e.g. Lutetium-177) anti-CD38. One concern is that excessively 
high radioactivity exposure of the adjacent bone marrow may also affect other hematopoietic 
cells. Further research with radiolabelled anti-CD38 and radio/immunotherapy is needed to 
address these questions.
This thesis describes the use of somatostatin receptor scintigraphy (SRS) SPECT and compares 
it to [18F]-FDG-PET. SRS-SPECT was inferior to [18F]-FDG-PET for detecting focal bone lesions. 
However, SRS-SPECT is limited by the moderate resolution of SPECT compared with PET. New 
[68Ga]-labeled somatostatin receptor based PET compounds are currently available that 
provide better imaging techniques for these receptors. Studies in the diagnostic work-up 
for neuroendocrine tumors (NET) with somatostatin labeled PET compounds have shown 
that [68Ga]-DOTA-TOC/-TATE/-NOC/-lanreotide PET/CT has superior resolution and thus 
better sensitivity than conventional SRS-SPECT, replacing SRS-SPECT for staging NET by PET/
CT. As somatostatin receptors are highly expressed on malignant plasma cells, [68Ga]-DOTA 
subtypes are potentially diagnostically useful in MM. 
MRI is frequently used in the diagnostic process of MM, particular for the spine and pelvis. 
MRI has a high sensitivity for visualizing focal and, more specifically, diffuse plasma cell 
infiltration of the bone marrow.
The role of novel MRI sequences is another area for further study. Diffusion weighted imaging 
(DWI) and delayed contrast enhancement (DCE) seem to improve the diagnostic properties 
of MRI in MM patients. Furthermore, nuclear imaging techniques can be combined with 
the MRI, for example FDG-PET/MRI, which combines metabolic information with anatomical 
information from the MRI. [18F]-FDG-PET/CT has been compared to FDG-PET/MRI in MM 
patients. Lesions detected with [18F]-FDG-PET/CT were also detected by FDG-PET/MRI, but 
whether this provides better diagnostic and prognostic value requires further evaluation. 
Response monitoring with MRI is difficult, but is improved when combined with PET. PET/
MRI systems are not yet widely available, and further investigation and optimization of PET/










































New quantification methods using [18F]-FDG-PET are currently available. Total lesion 
glycolysis (TLG) and metabolic tumor volume (MTV) can be calculated using [18F]-FDG-PET 
and may be more accurate than conventional SUV measurements for predicting overall tumor 
burden of focal lesions in MM. Initial data for TLG and MTV in MM are available. TLG and 
MTV were strongly associated with overall survival (OS) and progression-free survival (PFS), 
making them interesting prognostic markers2. International guidelines need to be developed 
to standardize TLG and MTV calculation in order to use these data in clinical research and 
trial settings.
Due to the continued development of novel agents, treatment response in MM continues 
to improve. Monitoring treatment response has also improved over the years. Detection 
of minimal residual disease (MRD) in the bone marrow is possible, for example using 
multiparametric flow cytometry immunophenotyping or next-generation sequencing. 
However, plasma cell infiltration of the bone marrow in multiple myeloma can be patchy, 
thus increasing the risk of a false negative MRD assessment. Nuclear imaging can be used to 
evaluate and monitor response to treatment by detecting metabolic activity over the whole 
body. Data on response evaluation after treatment, both autologous stem cell transplantation 
(ASCT) and chemotherapy only, show that a negative [18F]-FDG PET/CT scan is associated 
with prolonged time-to-progression compared to patients with a positive [18F]-FDG PET/CT 
for ASCT-eligible and ASCT-ineligible patients3. 
In the future, MRD screening may be useful for determining the duration of maintenance 
treatment after ASCT, or after chemotherapy for ASCT-ineligible patients. Maintenance 
treatment may result in side effects and is costly. Identifying which patients may benefit 
from maintenance treatment is an important step towards better personalized medicine. 
A randomized study in which MM patients are randomized to short-term or long-term 
maintenance treatment stratified by MRD status may provide valuable insights. If MRD 
positive patients show more benefit from maintenance than MRD negative patients, it will 
underline the need of nuclear imaging techniques for treatment monitoring.
In some patients, the disease is not systemic, but consists of a solitary lesion of monoclonal 
plasma cells called a plasmacytoma. The current treatment strategy for a solitary 
plasmacytoma is local radiotherapy (RT) with 40Gy. This appears to be the best treatment 
for extramedullary plasmacytoma (EMP), as only a small percentage of patients with an EMP 
will progress to MM. On the other hand, solitary plasmacytomas of the bone (SBP) have a 
very high rate of progression to MM, as described in this thesis. Therefore these patients 
may benefit from systemic treatment. Recent studies suggest that patients with a SBP and 
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progression to MM. It would be of interest to evaluate whether this group would benefit 
from adding systemic treatment to local radiotherapy, such as treatment with Daratumumab, 
bortezomib and dexamethasone for 6-12 months following RT. This may prolong the PFS to 
MM, or perhaps cure patients of their plasma cell neoplasms.
Venous thrombotic events (VTE) are one of the main complications of MM and its 
treatment. This thesis reports on the real-life incidence of VTE in newly diagnosed MM 
patients in the northern region of the Netherlands. The real-life incidence of VTE exceeds 
the incidence described in patients enrolled in studies. Guidelines should emphasize this 
fact, and thromboprophylaxis should be considered more frequently, not only during use of 
immunomodulating drugs, but also tailored to patient and treatment-specific characteristics. 
Furthermore, direct-acting oral anticoagulants (DOAC) are currently being used for prevention 
and treatment of VTE. DOAC are more convenient; they can be taken orally every day and 
without the need for blood monitoring. Therapeutic use of DOAC during induction treatment 
for MM might prevent VTE more effectively than prophylactic use of LMWH. However, studies 
are needed to conform this.
Finally, this thesis focuses on rare diseases related to the plasma cell. Scleromyxedema has 
a very low incidence, but recognizing and relating it to the plasma cell is very important, 
since treatment based on the underlying plasma cell neoplasm results in very good 
patient outcome. The same holds true for POEMS syndrome. POEMS is an acronym for 
polyneuropathy, organomegaly, endocrinopathy, monoclonal paraprotein (M-protein) and 
skin changes. This very debilitating disease responds strongly to targeted plasma cell therapy. 
We retrospectively studied the treatment results in 27 patients diagnosed with POEMS in the 
Netherlands. Mean age was 51 years, 67% was male and median follow-up was 32 months. 
Induction treatment with lenalidomide/dexamethasone was used in 56% of patients and was 
effective in 73%. In total, 17 patients received ASCT as primary (48%) or secondary (15%) 
therapy. No disease relapse or mortality was seen after ASCT. However, in three patients 
ineligible for ASCT developed a relapse of POEMS syndrome. Based on these findings and 
the previous studies, we concluded that upfront treatment of POEMS syndrome patients 
should include ASCT. Recognizing POEMS disease and performing the full diagnostic workup 
in these patients are crucial steps for correct treatment selection and response monitoring. 
Considering the very low incidence of this disease and the diagnostic workup and follow up, 
treatment should be concentrated in a limited number of centers with expertise in myeloma 
treatment. This would improve outcomes, enable sharing of expertise and provide more 
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De plasmacel is een witte bloedcel in het beenmerg die zorgt voor de productie van 
antistoffen. Dit zijn eiwitten die een rol spelen bij de afweer. Kwaadaardige ziekte van de 
plasmacel kunnen ontstaan wanneer één soort plasmacel (de zogenaamde monoklonale 
plasmacel) gaat woekeren, dit kan een heel scala aan ziektebeelden geven. Plasmacellen van 
een soort maken een soort antistof, dit noemen we het M-proteine.
Het Multipel Myeloom (MM), in Nederland ook wel de ziekte van Kahler genoemd, is het 
meest bekende ziektebeeld gerelateerd aan een woekering van monoklonale plasmacellen. 
Behandeling van MM gebeurt met chemotherapie. De behandeling wordt gestart als er 
problemen zijn die gerelateerd zijn aan de ziekte. Deze problemen worden ook wel de 
CRAB criteria genoemd en bestaan uit, een te hoog calcium in het bloed (C), nierfunctie 
stoornissen (R), bloedarmoede (A) of botaantasting door de plasmacellen (B). Botaantasting 
door de plasmacellen kan veel problemen geven voor patiënten. Het kan erg pijnlijk zijn en 
in het slechtste geval kunnen botten ook breken. Het opsporen van deze botafwijkingen 
gebeurt door middel van beeldvorming met röntgenfoto´s of een CT-scan. Dit weerspiegelt 
de anatomische weergave van de botstructuur. Daarnaast kan men ook gebruik maken 
van de zogenaamde nucleaire beeldvorming. Hierbij maakt men gebruik van biologische 
eigenschappen van de (kwaadaardige) cel. Tijdens het scannen wordt gebruik gemaakt van 
tracers (een radioactief gelabeld stofje). Deze tracers binden zich in het lichaam aan specifiek 
kenmerken van kwaadaardige cellen. In het geval van 18F-FDG-PET scan wordt radioactief 
gelabeld suiker gebruikt. Dit bindt aan receptoren waarmee de suikers in de cel worden 
getransporteerd. Versnelde opname hiervan wordt o.a. gezien bij snel delende kwaadaardige 
processen. Momenteel wordt er veel onderzoek gedaan naar de optimale scan methode 
om de botaantasting bij MM op te speuren. Ook wordt er gekeken in hoeverre deze scans 
voorspellend zijn voor de ziekte vooruitzichten. 
MM reageert vaak goed op chemotherapie alleen is het helaas wel zo dat de ziekte vroeg of 
laat weer terug komt. We spreken dan van een recidief van het MM. Ook in die situatie is het 
belangrijk om opnieuw te kijken naar botaantasting.
Naast het MM zijn er ook andere ziekten gerelateerd aan de kwaadaardige plasmacel. Deze 
ziekten kunnen een heel scala aan klachten veroorzaken. Ze zijn zeldzaam en soms moeilijk 
vast te stellen. Vaak worden deze ziekte op een zelfde manier behandeld als MM en met goed 
resultaat.
Het doel van dit proefschrift is om verschillende aspecten van de kwaadaardige plasmacel toe 










































Hoofdstuk 2 geeft een overzicht van verschillende nucleaire tracers (een radioactief gelabeld 
stofje) die gebruikt kunnen worden om MM activiteit op te sporen. Nucleaire beeldvorming 
kan in sommige gevallen ook gebruikt worden om effect van behandeling te monitoren.
In hoofdstuk 3 hebben we specifiek gekeken naar gewone röntgen foto’s, 18F-FDG-PET 
scan en de somatostatine receptor scintigrafie (SRS). Tot enkele jaren geleden werd voor 
het opsporen van botaantasting door MM gebruik gemaakt van gewone röntgen foto’s. Er 
moet meer dan 30% aantasting zijn voordat dit zichtbaar wordt op gewone röntgen foto’s. 
Bovendien blijven de afwijkingen zichtbaar op de foto’s, ook na behandeling. Dit betekent 
dat deze techniek moeilijk te gebruiken is om het effect van behandeling te monitoren. Het 
is bekend dat kwaadaardige plasmacellen een verhoogd aantal somatostatine receptoren op 
hun oppervlakte hebben. Middels SRS kun je deze receptoren zichtbaar maken. Het doel van 
dit onderzoek is om te kijken welke beeldvormende techniek het beste gebruikt kan worden 
om botaantasting aan te tonen bij patiënten die opnieuw ziekteactiviteit vertonen van het 
MM. De resultaten laten zien dat 18F-FDG-PET scan het meest waardenvol is. 
In hoofdstuk 4 hebben we gekeken of de afwijkingen zichtbaar op de 18F-FDG-PET scan 
ook verklaard kunnen worden door een verlaagd zuurstof gehalte in de tumor. Tijdens het 
maligne proces worden er veel voedingsstoffen en ook zuurstof gebruikt om te groeien. Uit 
bestaand onderzoek weten we dat er in de haarden met MM activiteit het zuurstof gehalte 
verlaagd kan zijn. Ook is er duidelijk toename van nieuwe bloedvaatjes in de MM haarden. 
De 18F-Fluoroazomycin arabinoside (18F-FAZA) scan is een methode om het zuurstof 
gehalte te meten. Bij patiënten met haarden op de 18F-FDG-PET scan hebben we ook een 
18F-FAZA scan gemaakt. De haarden waren echter niet terug te vinden op de 18F-FAZA scan. 
Doormiddel van kleuring op het beenmerg hebben we wel verschillende markers aan kunnen 
tonen die een rol spelen in de vorming van nieuwe bloedvaatjes in MM haarden. Aanwijzing 
voor directe hypoxie (zuurstof tekort) konden we via de 18F-FAZA scan niet aantonen.
Hoofdstuk 5 beschrijft een onderzoek in Noord-Nederland waarbij patiënten met een 
recidief MM worden behandeld met een combinatie van bortezomib, dexamethason en lage 
dosis orale cyclofosfamide. Vervolgens zijn de patiënten een jaar lang behandeld met een 
onderhoudsbehandeling bestaande uit bortezomib en cyclofosfamide. Het onderzoek heeft 
aangetoond dat bortezomib, dexamethason en lage dosis orale cyclofosfamide effectief is en 












































Trombose (het vormen van een bloedpropje in de aders) is een veel voorkomende complicatie 
bij het MM. Behandeling met bepaalde medicamenten tegen het MM de zo genoemde IMiD’s 
maakt dit risico nog groter. In hoofdstuk 6 wordt een analyse beschreven van het voorkomen 
van trombose bij MM patiënten. De gegevens van twee datasets in Noord-Nederland zijn 
gebruikt om te kijken hoe vaak trombose voorkomt in de totale groep aan MM patiënten. 
Daarnaast is gekeken hoe effectief medicamenten zijn die trombose moeten voorkomen. De 
resultaten laten zien dat trombose vaak voorkomt bij patiënten met MM, ook bij patiënten 
die geen IMiD gebruiken. Het gebruik van middelen om trombose te voorkomen moet 
intensiever toegepast worden en mogelijk moet de dosering ook hierop worden aangepast.
Het laatste onderdeel van dit proefschrift beschrijft zeldzame aandoeningen gerelateerd 
aan de plasmacel ziekte. Hoofdstuk 7 beschrijft gegevens uit Noord-Nederland omtrent het 
voorkomen van “een haard” van plasmacellen in het lichaam, het zogenaamde plasmacytoma. 
Plasmacytoma patiënten hebben een plaatselijke ophoping van plasmacellen in het lichaam 
zonder verdere tekenen van MM. Patiënten met een plasmacytoma worden plaatselijk 
behandeld met radiotherapie. De resultaten van deze studie laten zien dat patiënten met een 
plasmacytoma in de botten een veel grotere kans hebben om uiteindelijk MM te ontwikkelen 
dan patiënten met een plasmacytoma buiten de botten. Geen andere parameters werden 
gevonden om dit hoger risico te voorspellen.
Hoofdstuk 8 beschrijft de zeldzame ziekte scleromyxoedeem. Dit is een ziekte waarbij de 
huid en slijmvliezen steeds stugger worden en er veel klinische problemen kunnen optreden. 
Bijzonder is dat deze patiënten ook een M-proteïne hebben. Behandeling gericht tegen 
plasmacelziekte geeft vaak een langdurige verbetering van deze ziekte. In dit hoofdstuk 
wordt een patiënte beschreven die behandeld is met thalidomide en dexamethason gevolgd 































































































































































Prof. dr. E. Vellenga, Beste Edo, onze samenwerking is al heel wat jaar geleden begonnen 
toen je me vroeg of ik interesse had om onderzoek te doen. Zonder jouw begeleiding was dit 
proefschrift er nooit gekomen. Je houdt me bij de les, geeft kritisch commentaar maar gaf 
me ook de ruimte als die nodig was. Ik weet dat je altijd achter me staat. Mijn dank hiervoor 
is groot.
Prof. dr. R.H.J.A. Slart, Beste Riemer, jij bracht een hele andere invalshoek in het onderzoek 
door te denken vanuit de nucleaire geneeskunde. Onze discussies en jouw praktisch kant van 
zaken benaderen waardeer ik enorm. Stukken corrigeren doe je van over de hele wereld, in 
rap tempo. Dank voor je grote bijdrage aan mijn proefschrift.
De leden van de leescommissie, prof. dr. G.A. Huls, prof. dr. prof. dr. R.A.J.O. Dierckx en prof. 
dr. S. Zweegman, dank voor het beoordelen van mijn proefschrift. 
Prof. dr. J.C. Kluin - Nelemans, Beste Hanneke, onder jouw vleugels ben ik de hematoloog 
geworden die ik nu ben. Je hebt me een brede kennis gegeven over de hematologie en 
zelfvertrouwen door het vertrouwen wat je in mij had. 
Prof. dr. G.A. Huls, Beste Gerwin, in mijn stellingen haal ik een zin aan dat een goede dokter, 
een dokter is die zijn kennis naar de patiënt goed over kan brengen. Hierbij heb ik jou in mijn 
gedachten. Jouw manier van omgaan met patiënten heb ik hopelijk voor een deel met mij 
meegenomen. Ik wens je heel veel succes als afdelingshoofd.
Prof dr. K. Meijer, Beste Karina, heel praktisch en efficiënt. Sterk met onderzoek. Diepe 
bewondering hoe je dat allemaal voor elkaar speelt. Dank voor je hulp en af en toe even 
kletsen bij de koffie.
Beste Marcel, Marco, Bart, Mar, Goda, Anja, Carin, Martijn, Manu, Tom, Wouter en fellows 
dank voor de fijne samenwerking. Toen ik in het UMCG werkte maar ook nu op afstand vanuit 
het MCL. Jullie hulp en laagdrempeligheid waardeer ik enorm.
Beste Sylvia en Else, wat heerlijk dat ik altijd even bij jullie binnen kon vallen. Dank voor jullie 
hulp.
Maatschap Interne Geneeskunde MCL, Marjoke en Louise, ik ben erg blij dat ik een van de 
maten ben. Ik voel me thuis bij jullie en bij mijn werk in het MCL. Al is het druk en komt het 










































Beste Froukje, mijn coach, ik hoop dat je weet dat ik je erg dankbaar bent voor onze gesprekjes. 
Ik hoop nog vaak op je sofa te mogen plaatsnemen.
Beste Mels, al heel wat jaren geleden zei iemand tegen mij “je wordt toch geen oncoloog jij 
moet hematoloog worden”. Je had me geen beter advies kunnen geven, wat een mooi vak 
hebben wij. Dank voor de goede samenwerking en het feit dat je me uitdaagt om buiten me 
comfort zone te komen.
Beste Roos en Bas, ik voel me thuis binnen onze groep. We vullen elkaar aan, dagen elkaar uit 
en staan er voor elkaar. Ik hoop dat we nog vele jaren op deze manier zullen samenwerken.
Beste Annemarie, Marije, Bertha, Leny en Sanne, zonder jullie hulp was mijn werk niet te 
doen. Elke dag ben ik jullie dankbaar voor jullie hulp, jullie waakzaamheid en gezelligheid, ik 
hoop dat wij nog lang een team mogen vormen.
Beste afdeling Z, Y en team OCL, wat een goed en hecht team zijn jullie en wat ben ik blij dat 
ik daarbij mag horen. Niks is teveel en alles kan. Ik hoop nog heel lang met jullie samen te 
werken.
Lieve Afketsers, met de meeste van jullie ga ik al heel wat jaren terug, VWO op de RSG in 
Enkhuizen. Samen volleyballen en met de jaren hebben wij een hele hechte vriendschap 
opgebouwd. Al hebben wij West-Friesland ingeruild voor Friesland de band blijft erg hecht. 
Echt thuiskomen doe ik als we de Dijk overrijden en Enkhuizen zien liggen. Ik hoop dat we nog 
heel lang plezier met elkaar mogen beleven en bij elkaar zullen zijn in moeilijke momenten. 
Weten dat je hele goede vrienden hebt is goud waard.
Lieve Marlies, wij gaan nog veel langer terug. Als ik alles ga opnoemen zijn mijn bladzijdes 
gevuld. Maar ik zal nooit meer aan je vragen of je wilt strijken. Dank voor je altijd aanwezige 
vriendschapsliefde. Wij gaan nooit uit elkaar.
Lieve Jannie en fam van Dijk, jij zorgt ervoor dat de fam Laan draait. Jarenlang ben je de oppas 
van Jesper geweest en ook nu ben je onze steun en toeverlaat, een opgeruimd hoofd begint 
bij een opgeruimd huis. Dank.
Lieve Odette, Roelina en Linda, wat ontzettend gezellig dat we in de Knipe zo’n leuk clubje 











































Lieve fam Vroegh, weten dat de deur letterlijk en figuurlijk altijd open staat geeft ons een erg 
goed gevoel.
Lieve Familie Laan, dank voor jullie gezelligheid en steun. Karin op jouw kunnen we altijd een 
beroep doen. Samen zijn we door het verlies van Koos heen gegaan en zijn we een hechte 
familie. Onze dank is groot. Tante Kim zonder jou hulp draait het gezin Laan niet. Het zegt al 
genoeg dat je bij menig ouder in de Knipe in de telefoon staat onder Tante Kim…
Lieve Djamilla, we leerden elkaar kennen heel wat jaartjes geleden op de ASH in New Orleans. 
Vanaf dat moment gaan we altijd samen op congres. Je bent mijn maatje, weet hoe het vak 
werkt. Met jou kan ik sparren (en klagen). Samen met Edith een middagje shop till you drop 
doet me altijd goed. Ik ben je ontzettend dankbaar dat je naast me staat.
Lieve Veronica, eigenlijk moet ik je weer eens een brief schrijven, want zo zijn we begonnen 
als penvriendinnen. Inmiddels ben je zoveel meer. Onze kinderen zijn 8 handen op een buik. 
Wij zijn erg dankbaar dat jullie onze vrienden zijn. Ik hoop dat we nog heel veel moois samen 
mogen beleven. 
Lieve Jeroen en Patricia en Sander en Jessica, het hebben van twee broers is mij heel erg 
dierbaar. Samen opgroeien schept een hechte band. Met jullie humor geven jullie menig 
familie evenement kleur. Ik hou van jullie.
Lieve Pap en Mam, als we het over thuishoren hebben, dan zijn jullie dat natuurlijk echt. Ik 
hoor bij jullie. Jullie zijn er altijd, hebben me gestimuleerd op mijn weg die ik tot nu toe heb 
bewandeld, ik ben jullie ontzettend dankbaar. Ik hou van jullie.
Lieve Peter, mijn echte teamgenoot, mijn soulmate, mijn lief. Samen doen we het maar mooi 
wel even. Al zeg je dat jij niks aan dit proefschrift hebt gedaan, het tegendeel is waar. Jij bent 
de rots in ons gezin. Ik hou van je.
Lieve Jesper en Thomas, op jullie geboortekaartjes staat “te mooi voor woorden” en “zo puur 






















































































Esther de Waal werd op 28 oktober 1977 geboren in Alkmaar. Zij behaalde in 1995 haar 
VWO diploma aan de Rijksscholengemeenschap te Enkhuizen. Van 1995 tot 1999 studeerde 
zij Medische Biologie aan de Vrije Universiteit van Amsterdam, waar zij in december 1999 
haar doctoraal examen behaalde. In 1998 startte zij met de studie Geneeskunde aan de Vrije 
Universiteit van Amsterdam. In 2003 heeft ze haar artsexamen behaald. Van begin 2004 tot 
april 2004 was zij ANIOS Interne Geneeskunde in het Medisch Centrum Alkmaar. Omdat zij in 
april 2004 naar Friesland verhuisde, werd dit voortgezet in het Medisch Centrum Leeuwarden. 
In september 2004 startte zij met de opleiding Interne Geneeskunde met als opleiders Prof.
dr. R.O.B. Gans en dr. C. Halma. In februari 2009 volgde de subspecialisatie Hematologie 
aan de afdeling Hematologie van het UMCG Groningen onder begeleiding van Prof.dr. J.C. 
Kluin–Nelemans. In augustus 2011 vond registratie plaats tot internist-hematoloog. Van 
augustus 2011 tot juni 2014 is zij werkzaam geweest als internist-hematoloog aan de afdeling 
Hematologie van het UMCG Groningen. Sinds juli 2014 maakt zij deel uit van de maatschap 
Interne Geneeskunde van het Medisch Centrum Leeuwarden waar zij werkt als internist-
hematoloog.
Tijdens de opleiding tot hematoloog en haar werkzaamheden als internist-hematoloog in het 
UMCG Groningen werden de studies uitgevoerd die in dit proefschrift beschreven staan. Dit 
gebeurde onder leiding van Prof. dr. E. Vellenga en Prof. dr. R.H.J.A. Slart.
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